Teleflex (TFX) 10-Q 1 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	TFX
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Central Index Key	96,943
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		45,982,120

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Income Statement [Abstract]
Net revenues	$ 609,672	$ 534,703	$ 1,806,768	$ 1,551,197
Cost of goods sold	267,099	239,476	788,147	710,126
Gross profit	342,573	295,227	1,018,621	841,071
Selling, general and administrative expenses	214,894	163,771	660,148	486,674
Research and development expenses	26,365	21,194	78,410	59,299
Restructuring and impairment charges (credits)	19,209	(92)	77,625	13,723
Income from continuing operations before interest, loss on extinguishment of debt and taxes	82,105	110,354	202,438	281,375
Interest expense	27,171	21,264	79,763	58,884
Interest income	(320)	(286)	(776)	(616)
Loss on extinguishment of debt	0	0	0	5,593
Income from continuing operations before taxes	55,254	89,376	123,451	217,514
(Benefit) taxes on income from continuing operations	(1,286)	9,978	14,532	19,404
Income from continuing operations	56,540	79,398	108,919	198,110
Operating income (loss) from discontinued operations	(83)	(3,749)	1,246	(4,597)
Tax (benefit) on income (loss) from discontinued operations	(67)	(1,366)	(47)	(1,675)
Income (loss) from discontinued operations	(16)	(2,383)	1,293	(2,922)
Net income	$ 56,524	$ 77,015	$ 110,212	$ 195,188
Basic:
Income from continuing operations (in dollars per share)	$ 1.23	$ 1.76	$ 2.39	$ 4.40
Income (loss) from discontinued operations (in dollars per share)	0	(0.05)	0.03	(0.06)
Net income (in dollars per share)	1.23	1.71	2.42	4.34
Diluted:
Income from continuing operations (in dollars per share)	1.21	1.70	2.33	4.24
Loss from discontinued operations (in dollars per share)	0	(0.05)	0.03	(0.06)
Net income (in dollars per share)	1.21	1.65	2.36	4.18
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 1.02	$ 1.02
Weighted average common shares outstanding
Basic (in shares)	45,851	45,035	45,587	44,975
Diluted (in shares)	46,815	46,587	46,785	46,673

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Statement of Comprehensive Income [Abstract]
Net income	$ 56,524	$ 77,015	$ 110,212	$ 195,188
Other comprehensive (loss) income, net of tax:
Foreign currency translation, net of tax of $(3,505), $(8,429), $0, and $(26,910), for the three and nine months periods, respectively	14,387	43,345	(30,130)	156,012
Pension and other postretirement benefit plans adjustment, net of tax of $(363), $(479), $(1,253), and $(1,476) for the three and nine month period, respectively	1,215	743	4,111	2,337
Derivatives qualifying as hedges, net of tax of $(308), $141, $(419) and $(1,029) for the three and nine month period, respectively	1,651	(243)	1,943	4,918
Other comprehensive (loss) income, net of tax:	17,253	43,845	(24,076)	163,267
Comprehensive income	$ 73,777	$ 120,860	$ 86,136	$ 358,455

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Statement of Comprehensive Income [Abstract]
Foreign currency translation, tax	$ (3,505)	$ (8,429)	$ 0	$ (26,910)
Pension and other postretirement benefits plans adjustment, tax	(363)	(479)	(1,253)	(1,476)
Derivatives qualifying as hedges, tax	$ (308)	$ 141	$ (419)	$ (1,029)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 356,276	$ 333,558
Accounts receivable, net	374,341	345,875
Inventories, net	411,066	395,744
Prepaid expenses and other current assets	55,173	47,882
Prepaid taxes	40,715	5,748
Assets held for sale	3,239	0
Total current assets	1,240,810	1,128,807
Property, plant and equipment, net	421,265	382,999
Goodwill	2,223,429	2,235,592
Intangible assets, net	2,262,818	2,383,748
Deferred tax assets	2,305	3,810
Other assets	50,093	46,536
Total assets	6,200,720	6,181,492
Current liabilities
Current borrowings	77,250	86,625
Accounts payable	97,628	92,027
Accrued expenses	105,584	96,853
Current portion of contingent consideration	102,664	74,224
Payroll and benefit-related liabilities	94,132	107,415
Accrued interest	20,623	6,165
Income taxes payable	13,347	11,514
Other current liabilities	38,065	9,053
Total current liabilities	549,293	483,876
Long-term borrowings	2,075,834	2,162,927
Deferred tax liabilities	606,082	603,676
Pension and postretirement benefit liabilities	99,350	121,410
Noncurrent liability for uncertain tax positions	13,170	12,296
Noncurrent contingent consideration	141,910	197,912
Other liabilities	208,016	168,864
Total liabilities	3,693,655	3,750,961
Commitments and contingencies
Total shareholders' equity	2,507,065	2,430,531
Total liabilities and shareholders' equity	$ 6,200,720	$ 6,181,492

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017
Cash flows from operating activities of continuing operations:
Net income	$ 110,212	$ 195,188
Adjustments to reconcile net income to net cash provided by operating activities:
(Income) loss from discontinued operations	(1,293)	2,922
Depreciation expense	44,517	42,390
Amortization expense of intangible assets	111,974	63,976
Amortization expense of deferred financing costs and debt discount	3,548	3,940
Loss on extinguishment of debt	0	5,593
Fair value step up of acquired inventory sold	0	10,442
Changes in contingent consideration	47,344	(109)
Impairment of long-lived assets	19,110	0
Stock-based compensation	16,469	14,519
Deferred income taxes, net	8,664	(15,682)
Other	(13,028)	(13,559)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(29,830)	6,428
Inventories	(19,665)	(20,257)
Prepaid expenses and other current assets	(6,468)	(4,009)
Accounts payable, accrued expenses and other liabilities	54,581	24,128
Income taxes receivable and payable, net	(43,191)	3,798
Net cash provided by operating activities from continuing operations	302,944	319,708
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(55,751)	(53,977)
Proceeds from sale of assets	0	6,332
Payments for businesses and intangibles acquired, net of cash acquired	(22,550)	(1,010,711)
Net cash used in investing activities from continuing operations	(78,301)	(1,058,356)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	1,963,500
Reduction in borrowings	(98,500)	(747,576)
Debt extinguishment, issuance and amendment fees	(188)	(19,114)
Net proceeds from share based compensation plans and the related tax impacts	18,666	4,739
Payments for contingent consideration	(73,152)	(245)
Dividends paid	(46,526)	(45,905)
Net cash provided by (used in) financing activities from continuing operations	(199,700)	1,155,399
Cash flows from discontinued operations:
Net cash used in operating activities	(701)	(1,140)
Net cash used in discontinued operations	(701)	(1,140)
Effect of exchange rate changes on cash and cash equivalents	(1,524)	58,173
Net increase in cash and cash equivalents	22,718	473,784
Cash and cash equivalents at the beginning of the period	333,558	543,789
Cash and cash equivalents at the end of the period	356,276	1,017,573
Non cash investing activities of continuing operations:
Property, plant and equipment additions due to build-to-suit lease transaction	28,147	0
Non cash financing activities of continuing operations:
Settlement and exchange of convertible notes with common or treasury stock	0	53,207
Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements	$ 56,075	$ 127,158

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Beginning Balance at Dec. 31, 2016					$ (438,717)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 195,188
Other comprehensive loss	163,267
Ending Balance at Oct. 01, 2017					(275,450)
Beginning Balance (in shares) at Dec. 31, 2017		46,871				1,704
Beginning Balance at Dec. 31, 2017	2,430,531	$ 46,871	$ 591,721	$ 2,285,886	(265,091)	$ (228,856)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	110,212			110,212
Cash dividends ($1.02 per share)	(46,526)			(46,526)
Other comprehensive loss	(24,076)				(24,076)
Settlements of warrants (in shares)						(412)
Settlements of warrants	(40)		(56,115)			$ 56,075
Shares issued under compensation plans (in shares)		(321)				(47)
Shares issued under compensation plans	33,020	$ 321	$ 29,315			$ 3,384
Deferred compensation (in shares)			(398)			(10)
Deferred compensation	868					$ 470
Ending Balance (in shares) at Sep. 30, 2018		47,192				1,235
Ending Balance at Sep. 30, 2018	$ 2,507,065	$ 47,192	$ 565,319	$ 2,352,648	$ (289,167)	$ (168,927)

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Statement of Stockholders' Equity [Abstract]
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 1.02	$ 1.02

Basis of presentation

Basis of presentation	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Note 1 — Basis of presentation The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our,” “Teleflex” and the “Company”) are prepared on the same basis as its annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair presentation of financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year. In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017 .

New accounting standards

New accounting standards	9 Months Ended
	Sep. 30, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, as amended by additional guidance issued in 2015 and 2016, is encompassed in FASB Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”) and is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and affects any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The Company adopted the new standard on January 1, 2018, applying the modified retrospective method to all of its contracts; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.2 million increase to the Company's opening balance of retained earnings on the adoption date. In addition, in connection with its adoption of the new guidance, the Company reclassified the reserve for product returns from a reduction of receivables to a liability. The reserve for returns and allowances was $4.6 million at September 30, 2018 . The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. Additional information and disclosures required by this new standard are contained in Note 3. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases, subject to an option to elect certain practical expedients. As a result, companies can elect to apply the transition approach either for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements or for leases existing at, or entered into after, the adoption date. The Company is currently evaluating this guidance to determine its impact on the Company’s consolidated results of operations, cash flows and financial position. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The Company adopted the new standard on January 1, 2018 using the modified retrospective method of adoption; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.8 million increase to the Company's opening balance of retained earnings on the adoption date. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. In March 2017, the FASB issued guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. The Company adopted this guidance on January 1, 2018; the impact was not material to the consolidated financial statements. In August 2017, the FASB issued guidance with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The new guidance provides for changes to current designation and measurement guidance for qualifying hedging relationships and to the method of presenting hedge results. In addition, the new guidance includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The new guidance is effective for reporting periods beginning after December 15, 2018, but the guidance permits early adoptions, and the Company adopted the guidance effective October 1, 2018; the adoption did not result in any cumulative-effect adjustments to retained earnings. In February 2018, the FASB issued new guidance to address a narrow-scope financial reporting issue that arose as a consequence of the Tax Cuts and Jobs Act ("the TCJA"). Existing guidance requires that deferred tax liabilities and assets be adjusted for a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The guidance is applicable even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in net income), such as amounts related to benefit plans and hedging activity. As a result, the tax effects of items within accumulated other comprehensive income (referred to as stranded tax effects) do not reflect the appropriate tax rate. The new guidance permits a reclassification of these amounts from accumulated other comprehensive income to retained earnings, thereby eliminating the stranded tax effects. The new guidance also requires certain disclosures about the stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The new guidance can be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate under the TCJA is recognized. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.

Net revenues

Net revenues	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Net revenues	Net revenues The Company primarily generates revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with the Company’s customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when the Company’s products are shipped from the manufacturing or distribution facility. For the Company’s OEM segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and the Company has an enforceable right to payment to the extent that performance has been completed. The Company markets and sells products through its direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers such as pharmacies, which comprised 86% , 10% and 4% of consolidated net revenues, respectively, for the nine months ended September 30, 2018 . Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice. The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) the Company does not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; (5) the Company classifies shipping and handling costs within cost of goods sold; and (6) with respect to the OEM segment, the Company has applied the practical expedient to exclude disclosure of remaining performance obligations as the contracts typically have a term of one year or less. The amount of consideration the Company receives and revenue the Company recognizes varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. The Company’s policy is to accept returns only in cases in which the product is defective and covered under the Company’s standard warranty provisions. When the Company gives customers the right to return products, the Company estimates the expected returns based on an analysis of historical experience. The reserve for returns and allowances was $4.6 million and $4.4 million as of September 30, 2018 and October 1, 2017 , respectively. In estimating customer rebates, the Company considers the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers (as the Company has a history of providing similar rebates on similar products to similar customers) and other relevant information. The reserve for customer incentive programs, including customer rebates, was $17.1 million and $10.2 million at September 30, 2018 and October 1, 2017 , respectively. The Company expects the amounts subject to the reserve as of September 30, 2018 to be paid within 90 days subsequent to period-end. The following table disaggregates revenue by global product category for the three and nine months ended September 30, 2018 and October 1, 2017 . Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 Revenue by global product category (1) (2) (Dollars in thousands) Vascular access $ 142,712 $ 133,521 $ 427,557 $ 396,866 Anesthesia 87,973 87,964 263,202 255,107 Interventional 79,404 69,186 228,262 181,577 Surgical 89,910 85,210 266,049 263,254 Interventional urology 48,995 — 138,969 — OEM 54,838 48,589 153,286 137,067 Other (3) 105,840 110,233 329,443 317,326 Net revenues $ 609,672 $ 534,703 $ 1,806,768 $ 1,551,197 (1) The product categories listed above are presented on a global basis; in contrast, the Company’s North American reportable segments generally are defined largely based on the particular products sold by the segments, and its non-North American reportable segments are defined exclusively based on the geographic location of segment operations (with the exception of the Original Equipment and Development Services ("OEM") reportable segment, which operates globally). The Company’s EMEA and Asia reportable segments, as well as its Latin America operating segment, include net revenues from each of the product categories listed above. (2) The methodology used to determine the product revenues included within certain of the product categories listed in the table above differs from the methodology used to classify revenues in our reportable segments, including the similarly named North American reportable segments. The differences are due to the fact that segment classification generally is determined based on the call point within the customer's organization from which the purchase order resulting in the sale originated, while the classification of products within the product categories listed in the table above includes all sales of products within the listed product category, regardless of the call point within the customer's organization from which the sale originated. (3) Other revenues in the table above include revenues related to sales of the Company’s respiratory, urology and cardiac products.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Acquisitions	Acquisitions On October 4, 2018, the Company acquired Essential Medical, Inc., a medical device company that developed the CE marked MANTA Vascular Closure Device, which is designed for closure of large bore arteriotomies and complements the Company's interventional product portfolio. See Note 16 for additional details. On June 21, 2018, the Company acquired certain assets of QT Vascular LTD ("QT Vascular"), a medical device company that developed and marketed coronary balloon catheters, which complement the Company's interventional product portfolio. The aggregate consideration transferred for the assets, which primarily consisted of intellectual property, was $20.6 million . The acquisition was accounted for as a business combination. 2017 Acquisitions During 2017, the Company completed several acquisitions; the largest of which were NeoTract, Inc. ("NeoTract") and Vascular Solutions, Inc. ("Vascular Solutions"), which are summarized below. The fair value of the consideration transferred for the 2017 acquisitions was $2.0 billion . NeoTract On October 2, 2017, the Company acquired NeoTract, a medical device company that developed and commercialized the UroLift System, a minimally invasive medical device for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. The Company made initial payments of $725.6 million in cash less a favorable working capital adjustment of $1.4 million . Additionally, the estimated fair value of contingent consideration related to NeoTract sales-based milestones as of September 30, 2018 was $229.4 million . The contingent consideration liability represents the estimated fair value of the Company’s obligations, under the acquisition agreement, to make additional payments of up to $ 300 million in the aggregate if specified sales goals through the end of 2020 are achieved. The Company made a payment of $75.0 million during 2018 as a result of the achievement of a sales goal for the period from January 1, 2018 to April 30, 2018. NeoTract financial information is primarily presented within the Interventional Urology North America operating segment, which is included in the "all other" category in the Company's presentation of segment information. Vascular Solutions On February 17, 2017, the Company acquired Vascular Solutions, a medical device company that developed and marketed products for use in minimally invasive coronary and peripheral vascular procedures. The aggregate consideration paid by the Company in connection with the acquisition was $975.5 million . Pro forma combined financial information The following unaudited pro forma combined financial information for the three and nine months ended October 1, 2017 gives effect to the Vascular Solutions and NeoTract acquisitions as if they had occurred on January 1, 2016. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. Three Months Ended Nine Months Ended October 1, 2017 October 1, 2017 (Dollars and shares in thousands, except per share) Net revenue $ 568,437 $ 1,660,591 Net income $ 52,909 $ 157,249 Basic earnings per common share: Net income $ 1.17 $ 3.50 Diluted earnings per common share: Net income $ 1.14 $ 3.37 Weighted average common shares outstanding: Basic 45,035 44,975 Diluted 46,587 46,673 The unaudited pro forma combined financial information presented above includes the accounting effects of the Vascular Solutions and NeoTract acquisitions, including, to the extent applicable, amortization charges from acquired intangible assets; adjustments for depreciation of property, plant and equipment; interest expense; and the related tax effects.

Restructuring charges and impai

Restructuring charges and impairment charges	9 Months Ended
	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring charges and impairment charges	Note 5 — Restructuring and impairment charges (credits) The following tables provide information regarding restructuring and impairment charges (credits) recognized by the Company for the three and nine months ended September 30, 2018 and October 1, 2017 : Three Months Ended September 30, 2018 Termination benefits Other costs (1) Total (Dollars in thousands) 2018 Footprint realignment plan $ 1,119 $ 145 $ 1,264 Other restructuring programs (2) 468 232 700 Restructuring charges $ 1,587 $ 377 $ 1,964 Asset impairment charges — 17,245 17,245 Restructuring and impairment charges $ 1,587 $ 17,622 $ 19,209 Three Months Ended October 1, 2017 Termination benefits Other costs (1) Total (Dollars in thousands) Restructuring (credits) charges (3) $ (554 ) $ 462 $ (92 ) Nine Months Ended September 30, 2018 Termination benefits Other costs (1) Total (Dollars in thousands) 2018 Footprint realignment plan $ 53,463 $ 275 $ 53,738 2016 Footprint realignment plan 2,379 417 2,796 Other restructuring programs (4) 1,318 663 1,981 Restructuring charges $ 57,160 $ 1,355 $ 58,515 Asset impairment charges — 19,110 19,110 Restructuring and impairment charges $ 57,160 $ 20,465 $ 77,625 Nine Months Ended October 1, 2017 Termination benefits Other costs (1) Total (Dollars in thousands) 2017 Vascular Solutions integration program $ 4,534 $ 92 $ 4,626 2017 EMEA restructuring program 5,822 84 5,906 2016 Footprint realignment plan 1,099 233 1,332 Other restructuring programs (5) 1,352 507 1,859 Restructuring charges $ 12,807 $ 916 $ 13,723 (1) Other costs include facility closure, contract termination, and other exit costs. (2) Other restructuring programs include the 2016 and 2014 Footprint realignment plans, the 2017 Vascular Solutions integration program, the 2017 EMEA restructuring program and the other 2016 restructuring programs. (3) Restructuring charges (credits) include activity related to the 2017 Vascular Solutions integration program, the 2017 EMEA restructuring program, the 2016 and 2014 footprint realignment plans, the 2017 Pyng integration program and the other 2016 restructuring programs. The Company committed to the 2017 Pyng integration program, which relates to the integration of Pyng Medical Corp. (“Pyng”) into the Company, during the second quarter of 2017, following the Company’s acquisition of Pyng in April 2017. (4) Other restructuring programs include the 2014 Footprint realignment plan, the 2017 Vascular Solutions integration program, the 2017 EMEA restructuring program and the other 2016 restructuring programs. (5) Other restructuring programs include the 2014 Footprint realignment plan, the 2017 Pyng integration program and the other 2016 restructuring programs. 2018 Footprint Realignment Plan On May 1, 2018, the Company initiated a restructuring plan involving the relocation of certain European manufacturing operations to existing lower-cost locations, the outsourcing of certain of the Company’s European distribution operations and related workforce reductions (the “2018 Footprint realignment plan"). These actions are expected to be substantially completed by the end of 2024. The following table provides a summary of the Company’s cost estimates by major type of expense associated with the 2018 Footprint realignment plan: Type of expense Total estimated amount expected to be incurred Termination benefits $60 million to $70 million Other exit costs (1) $2 million to $4 million Restructuring charges $62 million to $74 million Restructuring related charges (2) $40 million to $59 million Total restructuring and restructuring related charges $102 million to $133 million (1) Includes contract termination, facility closure, employee relocation, equipment relocation and outplacement costs. (2) Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to transfer manufacturing operations to the new locations, as well as a charge associated with the Company’s exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the charges are expected to be recognized within costs of goods sold. In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges with respect to the 2018 Footprint realignment plan of $1.8 million and $2.8 million for the three and nine months ended September 30, 2018 , respectively, within cost of goods sold. As of September 30, 2018 , the Company has a restructuring reserve of $51.6 million related to this plan, all of which related to termination benefits. 2016 Footprint Realignment Plan In 2016, the Company initiated a restructuring plan (the “2016 Footprint realignment plan") involving the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. These actions commenced in the first quarter of 2016 and are expected to be substantially completed by the end of 2018. In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges with respect to the 2016 Footprint realignment plan of $1.7 million and $5.1 million for the three and nine months ended September 30, 2018 and $1.4 million and $5.5 million for the three and nine months ended October 1, 2017 , respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2016 Footprint realignment plan of approximately $43 million . As of September 30, 2018 , the Company has incurred aggregate restructuring charges in connection with the 2016 Footprint realignment plan of $17.4 million . Additionally, as of September 30, 2018 , the Company has incurred aggregate restructuring related charges of $19.8 million with respect to the 2016 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations to new locations. The restructuring related charges primarily were included in cost of goods sold. As of September 30, 2018 , the Company has a restructuring reserve of $5.9 million related to this plan, all of which related to termination benefits. 2014 Footprint Realignment Plan In 2014, the Company initiated a restructuring plan (“the 2014 Footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020. In addition to the restructuring charges set forth in the tables above, the Company recorded restructuring related charges with respect to the 2014 Footprint realignment plan of $0.8 million and $1.8 million for the three and nine months ended September 30, 2018 , respectively, and $1.0 million and $ 3.1 million for the three and nine months ended October 1, 2017 , respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 Footprint realignment plan of $46 million to $51 million . As of September 30, 2018 , the Company has incurred aggregate restructuring charges of $12.4 million in connection with the 2014 Footprint realignment plan . Additionally, as of September 30, 2018 , the Company has incurred aggregate restructuring related charges of $28.7 million related to the 2014 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations from the existing locations to new locations. These restructuring related charges primarily were included in cost of goods sold. As of September 30, 2018 , the Company has a restructuring reserve of $3.8 million in connection with the plan, all of which related to termination benefits. As the restructuring programs progress, management will reevaluate the estimated expenses and charges set forth above, and may revise its estimates, as appropriate, consistent with GAAP. For additional information related to the Company's restructuring programs, see Note 4 to the Company's consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2017. Restructuring charges (credits) by reportable operating segment, and by all other operating segments in the aggregate, for the three and nine months ended September 30, 2018 and October 1, 2017 are set forth in the following table: Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) Vascular North America $ 203 $ 582 $ 725 $ 1,663 Interventional North America (26 ) (228 ) 881 4,178 Anesthesia North America 38 220 164 1,031 EMEA 1,520 (632 ) 54,310 6,483 All other 229 (34 ) 2,435 368 Restructuring charges $ 1,964 $ (92 ) $ 58,515 $ 13,723 Asset Impairment Charges During the third quarter 2018, the Company decided to abandon certain intellectual property and other assets associated with products that will be eliminated from the Company's interventional product portfolio. As a result, the Company recognized pre-tax impairment charges of $17.2 million ( $9.2 million after tax) for the three months ended September 30, 2018.

Inventories, net

Inventories, net	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventories, net	Inventories, net Inventories as of September 30, 2018 and December 31, 2017 consisted of the following: September 30, 2018 December 31, 2017 (Dollars in thousands) Raw materials $ 105,600 $ 98,451 Work-in-process 65,291 62,381 Finished goods 240,175 234,912 Inventories, net $ 411,066 $ 395,744

Goodwill and other intangible a

Goodwill and other intangible assets, net	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets, net	Note 7 — Goodwill and other intangible assets, net The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment, and by all other operating segments in the aggregate, for the nine months ended September 30, 2018 : Vascular Interventional North America Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) December 31, 2017 $ 264,869 $ 433,049 $ 157,289 $ 250,912 $ 494,548 $ 209,200 $ 4,883 $ 420,842 $ 2,235,592 Goodwill related to acquisitions — 1,027 — — (27 ) (9 ) — (413 ) 578 Currency translation adjustment — (1,934 ) (634 ) — (7,778 ) (3,079 ) — 684 (12,741 ) September 30, 2018 $ 264,869 $ 432,142 $ 156,655 $ 250,912 $ 486,743 $ 206,112 $ 4,883 $ 421,113 $ 2,223,429 The Company's gross carrying amount of, and accumulated amortization relating to, intangible assets as of September 30, 2018 and December 31, 2017 were as follows: Gross Carrying Amount Accumulated Amortization September 30, 2018 December 31, 2017 September 30, 2018 December 31, 2017 (Dollars in thousands) Customer relationships $ 1,020,603 $ 1,023,837 $ (314,051 ) $ (281,263 ) In-process research and development 29,377 34,672 — — Intellectual property 1,273,503 1,287,487 (305,350 ) (258,580 ) Distribution rights 23,637 23,697 (17,756 ) (16,996 ) Trade names 569,570 571,510 (33,001 ) (22,069 ) Non-compete agreements 23,672 23,429 (7,386 ) (1,976 ) $ 2,940,362 $ 2,964,632 $ (677,544 ) $ (580,884 ) During the third quarter 2018, the Company recognized a $16.9 million pre-tax ( $8.9 million after tax) impairment charge related to the abandonment of certain intellectual property intangible assets. Refer to Note 5 for additional details.

Financial instruments

Financial instruments	9 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Financial instruments On October 4, 2018, the Company executed cross-currency interest rate swaps to hedge against the effect of variability in the U.S. dollar to euro exchange rate. See Note 16 for additional details. Foreign Currency Forward Contracts The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage exposure related to foreign currency transactions. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. For the three and nine months ended September 30, 2018 the Company recognized a gain related to non-designated foreign currency forward contracts of $1.0 million and $0.3 million , respectively. For the three and nine months ended October 1, 2017 , the Company recognized a loss related to non-designated foreign currency forward contracts of $0.6 million and $3.7 million , respectively. The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of September 30, 2018 and December 31, 2017 : September 30, 2018 December 31, 2017 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 2,158 $ 914 Non-designated foreign currency forward contracts 175 307 Prepaid expenses and other current assets $ 2,333 $ 1,221 Total asset derivatives $ 2,333 $ 1,221 Liability derivatives: Designated foreign currency forward contracts $ 572 $ 1,373 Non-designated foreign currency forward contracts 1,064 53 Other current liabilities $ 1,636 $ 1,426 Total liability derivatives $ 1,636 $ 1,426 The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of September 30, 2018 and December 31, 2017 was $127.5 million and $88.5 million , respectively. The total notional amount for all open non-designated foreign currency forward contracts as of September 30, 2018 and December 31, 2017 was $124.6 million and $110.6 million , respectively. All open foreign currency forward contracts as of September 30, 2018 have durations of twelve months or less. There was no ineffectiveness related to the Company’s cash flow hedges during the three and nine months ended September 30, 2018 and October 1, 2017 . Concentration of Credit Risk Concentrations of credit risk with respect to trade accounts receivable are generally limited due to the Company’s large number of customers and their diversity across many geographic areas. However, a portion of the Company’s trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the creditworthiness of the healthcare systems in those countries and the financial stability of those countries' economies. Certain of the Company’s customers, particularly in Greece, Italy, Spain and Portugal, have extended or delayed payments for products and services already provided, raising collectability concerns regarding the Company’s accounts receivable from these customers. As a result, the Company continues to closely monitor the allowance for doubtful accounts with respect to these customers. The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at September 30, 2018 and December 31, 2017 : September 30, 2018 December 31, 2017 (Dollars in thousands) Allowance for doubtful accounts (1) $ 9,657 $ 10,255 Current and long-term trade accounts receivable, net in Greece, Italy, Spain and Portugal (2) $ 51,468 $ 49,054 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 14.1 % 14.6 % (1) The current portion of the allowance for doubtful accounts was $3.9 million and $3.5 million as of September 30, 2018 and December 31, 2017 , respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at September 30, 2018 and December 31, 2017 was $4.2 million and $3.3 million , respectively. For the nine months ended September 30, 2018 and October 1, 2017 , net revenues from customers in Greece, Italy, Spain and Portugal were $107.7 million and $96.0 million , respectively.

Fair value measurement

Fair value measurement	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement For a description of the fair value hierarchy, see Note 10 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017 . The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 9,849 $ 9,849 $ — $ — Derivative assets 2,333 — 2,333 — Derivative liabilities 1,636 — 1,636 — Contingent consideration liabilities 244,574 — — 244,574 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 9,045 $ 9,045 $ — $ — Derivative assets 1,221 — 1,221 — Derivative liabilities 1,426 — 1,426 — Contingent consideration liabilities 272,136 — — 272,136 There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the nine months ended September 30, 2018 . Valuation Techniques The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. The Company measures the fair value of the foreign currency forward contracts by calculating the amount required to enter into offsetting contracts with similar remaining maturities as of the measurement date, based on quoted market prices, and taking into account the creditworthiness of the counterparties. The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions, which are discussed immediately below. Contingent consideration As of September 30, 2018 , the Company estimates that contingent consideration payments will occur in 2018 through 2029, and the maximum amount of undiscounted payments the Company could make under contingent consideration arrangements is $325 million . The contingent consideration liabilities, which primarily consist of Company obligations payable if specified net sales goals are achieved, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates. The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The contingent consideration liability related to the NeoTract acquisition represents the estimated fair value of the Company's obligations to make additional payments of up to $300 million in the aggregate if specified sales goals are achieved. Specifically, the payments are based on net sales (as defined in the NeoTract acquisition agreement) for the years ended December 31, 2018, 2019 and 2020. The fair value of the contingent consideration related to the NeoTract acquisition was estimated using a Monte Carlo valuation approach, which simulates future revenues during the earn out-period using management's best estimates. The Company determines the value of its other contingent consideration liabilities based on a probability-weighted discounted cash flow analysis. Increases in projected revenues and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates may result in significantly lower fair value measurements; decreases in the discount rates may have the opposite effect. The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration recognized in connection with the NeoTract acquisition. Valuation Technique Unobservable Input Range Contingent consideration Monte Carlo simulation Revenue volatility 24.1 % Risk free rate Cost of debt structure Projected year of payment 2019 - 2021 The following table provides information regarding changes, during the nine months ended September 30, 2018 , in Level 3 financial liabilities related to contingent consideration: Contingent consideration 2018 (Dollars in thousands) Balance - December 31, 2017 $ 272,136 Additions (1) 396 Payments (2) (75,252 ) Revaluations 47,344 Translation adjustment (50 ) Balance - September 30, 2018 $ 244,574 (1) The Company established a liability related to the estimated fair value of contingent consideration associated with the acquired assets from QT Vascular. (2) Consists mainly of a $75.0 million payment resulting from the achievement of a sales goal associated with the NeoTract acquisition for the period from January 1, 2018 to April 30, 2018.

Shareholders' equity

Shareholders' equity	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Shareholders' equity	Shareholders’ equity Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Shares in thousands) Basic 45,851 45,035 45,587 44,975 Dilutive effect of share-based awards 919 934 1,007 873 Dilutive effect of convertible notes and warrants 45 618 191 825 Diluted 46,815 46,587 46,785 46,673 The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.7 million for the three and nine months ended September 30, 2018 and 0.6 million for the three and nine months ended October 1, 2017 . In connection with the issuance by the Company in 2010 of $400 million principal amount of convertible notes that matured in August 2017, and as part of hedging arrangements between the Company and two institutional counterparties, the Company issued warrants to the counterparties, entitling them to purchase Company common stock. These transactions are described in greater detail in Note 11 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017. At September 30, 2018, all of the warrants either (a) were canceled as a result of warrant unwind agreements between the Company and the counterparties or (b) were exercised by the counterparties. The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2018 and October 1, 2017 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2017 $ 340 $ (138,808 ) $ (126,623 ) $ (265,091 ) Other comprehensive income (loss) before reclassifications 2,816 127 (30,130 ) (27,187 ) Amounts reclassified from accumulated other comprehensive income (873 ) 3,984 — 3,111 Net current-period other comprehensive income (loss) 1,943 4,111 (30,130 ) (24,076 ) Balance as of September 30, 2018 $ 2,283 $ (134,697 ) $ (156,753 ) $ (289,167 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive (loss) before reclassifications 3,383 (1,050 ) 156,012 158,345 Amounts reclassified from accumulated other comprehensive loss 1,535 3,387 — 4,922 Net current-period other comprehensive income 4,918 2,337 156,012 163,267 Balance as of October 1, 2017 $ 2,494 $ (134,259 ) $ (143,685 ) $ (275,450 ) The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and nine months ended September 30, 2018 and October 1, 2017 : Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ (87 ) $ (1,179 ) $ (1,038 ) $ 1,769 Total before tax (87 ) (1,179 ) (1,038 ) 1,769 Taxes (benefit) 25 237 165 (234 ) Net of tax $ (62 ) $ (942 ) $ (873 ) $ 1,535 Amortization of pension and other postretirement benefit items (1): Actuarial losses $ 1,640 $ 1,723 $ 5,120 $ 5,176 Prior-service costs 24 20 71 79 Total before tax 1,664 1,743 5,191 5,255 Tax benefit (388 ) (619 ) (1,207 ) (1,868 ) Net of tax $ 1,276 $ 1,124 $ 3,984 $ 3,387 Total reclassifications, net of tax $ 1,214 $ 182 $ 3,111 $ 4,922 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continuing

Taxes on income from continuing operations	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Taxes on income from continuing operations	Taxes on income from continuing operations Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 Effective income tax rate (2.3)% 11.2% 11.8% 8.9% The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The legislation significantly changed U.S. tax law by, among other things, permanently reducing corporate income tax rates from a maximum of 35% to 21%, effective January 1, 2018; implementing a territorial tax system, by generally providing for, among other things, a dividends received deduction on the foreign source portion of dividends received from a foreign corporation if specified conditions are met; and imposing a one-time repatriation tax on undistributed post-1986 foreign subsidiary earnings and profits, which are deemed repatriated for purposes of the tax. In addition, the TCJA imposes two new U.S. tax base erosion provisions: (1) the global intangible low-taxed income ("GILTI") provisions and (2) the base erosion and anti-abuse tax ("BEAT") provisions, which are explained in more detail in Note 13 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017. In accordance with the applicable provisions of SEC Staff Accounting Bulletin No. 118, the Company included in its consolidated financial statements as of December 31, 2017 provisional amounts reflecting the tax impact related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities. During the third quarter of 2018, the Company recorded a $2.1 million tax benefit to adjust its initial provisional estimates for the TCJA in its provision for income taxes. The adjustment specifically related to the Company's initial estimate of the revaluation of certain deferred tax balances as a result of the reduced corporate income tax rate. To date, the Company has not made any other significant changes to its initial provisional estimates included in its consolidated financial statements as of December 31, 2017 and continues to evaluate the impact of the TCJA. Once the Company's accounting for the income tax effects of the TCJA is complete, the amounts with respect to the income tax effects of the TCJA may differ from the provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the TCJA. The effective income tax rate for the three and nine months ended September 30, 2018 was (2.3)% and 11.8% , respectively, and was 11.2% and 8.9% for the three and nine months ended October 1, 2017 , respectively. The effective income tax rate for the three and nine months ended September 30, 2018 as compared to the prior year periods reflects impacts of the TCJA, including the benefit of a lower U.S. corporate tax rate of 21.0% from the enactment of the TCJA, partially offset by a tax cost associated with GILTI. In addition, the effective tax rate for the three and nine months ended September 30, 2018 includes a tax benefit associated with the asset impairment charges described in Note 5, excess tax benefits associated with share based payments, and a non-deductible contingent consideration expense recognized in connection with an increase in the fair value of the NeoTract contingent consideration liability. The income tax rate for the nine months ended September 30, 2018 as compared to the prior year period reflects non-deductible termination benefits and other costs incurred in connection with the 2018 Footprint realignment plan. The effective tax rate for the nine months ended October 1, 2017 reflected a tax benefit associated with costs incurred in connection with the Vascular Solutions acquisition.

Pension and other postretiremen

Pension and other postretirement benefits	9 Months Ended
	Sep. 30, 2018
Retirement Benefits [Abstract]
Pension and other postretirement benefits	Pension and other postretirement benefits The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. As of September 30, 2018 , no further benefits are being accrued under the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement. Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits Pension Other Postretirement Benefits September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) Service cost $ 380 $ 725 $ (66 ) $ 61 $ 1,135 $ 2,162 $ 38 $ 210 Interest cost 3,681 3,773 285 426 11,119 11,347 1,042 1,183 Expected return on plan assets (7,423 ) (6,607 ) — — (22,260 ) (20,100 ) — — Net amortization and deferral 1,687 1,668 (23 ) 75 5,090 5,049 101 206 Net benefits expense (income) $ (1,675 ) $ (441 ) $ 196 $ 562 $ (4,916 ) $ (1,542 ) $ 1,181 $ 1,599

Commitments and contingent liab

Commitments and contingent liabilities	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Commitments and contingent liabilities Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At September 30, 2018 , the Company has recorded $1.0 million and $5.5 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of September 30, 2018 . The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 15 - 20 years. Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of September 30, 2018 , the Company has recorded accrued liabilities of $1.8 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various tax authorities. As of September 30, 2018 , the most significant tax examinations in process are in Germany and Italy. The Company may establish reserves with respect to its uncertain tax positions, after which it adjusts the reserves to address developments with respect to its uncertain tax positions, including developments in these tax examinations. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results. Other: The Company has various purchase commitments for materials, supplies and other items occurring in the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Segment information

Segment information	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment information	Segment information Following the Company's acquisition of Vascular Solutions, the Company commenced an integration program under which it is combining the Vascular Solutions' business with some of its legacy businesses. As a result, effective during the fourth quarter 2017, the Company realigned its operating segments. The changes to the operating segments were also made to reflect the manner in which the Company’s chief operating decision maker assesses business performance and allocates resources. The Company now has the following seven reportable segments: Vascular North America, Interventional North America, Anesthesia North America, Surgical North America, Europe, Middle East and Africa ("EMEA"), Asia and Original Equipment and Development Services ("OEM"). In connection with the presentation of segment information, the Company will continue to present certain operating segments, which currently include the Interventional Urology North America, Respiratory North America and Latin America operating segments, in the “all other” category because separate information with regard to each of these operating segments is not material. All prior comparative periods presented have been restated to reflect these changes. The following tables present the Company’s segment results for the three and nine months ended September 30, 2018 and October 1, 2017 : Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) Vascular North America $ 80,719 $ 75,065 $ 243,829 $ 232,872 Interventional North America 66,726 60,719 191,878 159,002 Anesthesia North America 53,160 50,819 154,215 148,107 Surgical North America 42,545 40,804 123,930 131,464 EMEA 139,541 137,034 452,826 409,077 Asia 76,544 74,202 207,201 190,368 OEM 54,838 48,589 153,286 137,067 All other 95,599 47,471 279,603 143,240 Net revenues $ 609,672 $ 534,703 $ 1,806,768 $ 1,551,197 Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) Vascular North America $ 24,287 $ 17,803 $ 73,585 $ 54,565 Interventional North America 17,142 12,485 47,772 13,265 Anesthesia North America 16,811 15,084 48,860 48,444 Surgical North America 15,906 13,618 47,709 47,285 EMEA 21,916 24,198 80,221 69,102 Asia 20,834 20,427 54,948 50,252 OEM 15,049 12,256 37,617 31,714 All other (5,587 ) 7,290 (43,162 ) 25,634 Total segment operating profit (1) 126,358 123,161 347,550 340,261 Unallocated expenses (2) (44,253 ) (12,807 ) (145,112 ) (58,886 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 82,105 $ 110,354 $ 202,438 $ 281,375 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets. The following table provides total net revenues by geographic region (based on the Company's selling location) for the three and nine months ended September 30, 2018 and October 1, 2017 : Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) United States $ 365,271 $ 306,763 $ 1,066,095 $ 903,201 Europe 160,498 148,808 500,697 434,223 Asia 60,414 59,169 170,458 156,074 All other 23,489 19,963 69,518 57,699 Net revenues $ 609,672 $ 534,703 $ 1,806,768 $ 1,551,197

Condensed consolidating guarant

Condensed consolidating guarantor financial information	9 Months Ended
	Sep. 30, 2018
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed consolidating guarantor financial information	Condensed consolidating guarantor financial information The Company’s $250 million principal amount of 5.25% Senior Notes due 2024 (the “2024 Notes”), $400 million principal amount of 4.875% Senior Notes due 2026 (the “2026 Notes”) and $500 million principal amount of 4.625% Senior Notes due 2027 (the “2027 Notes," and collectively with the 2024 Notes and the 2026 Notes, the "Senior Notes") are issued by Teleflex Incorporated (the “Parent Company”), and payment of the Parent Company's obligations under the Senior Notes are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The 2024 Notes, 2026 Notes and 2027 Notes are guaranteed by the same Guarantor Subsidiaries. The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income for the three and nine months ended September 30, 2018 and October 1, 2017 , condensed consolidating balance sheets as of September 30, 2018 and December 31, 2017 and condensed consolidating statements of cash flows for the nine months ended September 30, 2018 and October 1, 2017 , provide consolidated information for: a. Parent Company, the issuer of the guaranteed obligations; b. Guarantor Subsidiaries, on a combined basis; c. Non-Guarantor Subsidiaries (i.e., those subsidiaries of the Parent Company that have not guaranteed payment of the Senior Notes), on a combined basis; and d. Parent Company and its subsidiaries on a consolidated basis. The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidating financial information, except for the use of the equity method of accounting to reflect ownership interests in subsidiaries, which are eliminated upon consolidation. Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries. During the first quarter 2018, a Guarantor Subsidiary merged with and into Parent; the transaction was reflected as of the beginning of the earliest period presented in the condensed consolidating financial statements. TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 398,961 $ 322,010 $ (111,299 ) $ 609,672 Cost of goods sold — 232,209 146,301 (111,411 ) 267,099 Gross profit — 166,752 175,709 112 342,573 Selling, general and administrative expenses 11,347 130,773 72,796 (22 ) 214,894 Research and development expenses 378 19,482 6,505 — 26,365 Restructuring charges — 17,128 2,081 — 19,209 (Loss) income from continuing operations before interest and taxes (11,725 ) (631 ) 94,327 134 82,105 Interest, net 25,191 1,057 603 — 26,851 (Loss) income from continuing operations before taxes (36,916 ) (1,688 ) 93,724 134 55,254 (Benefit) taxes on (loss) income from continuing operations (13,449 ) (2,562 ) 14,712 13 (1,286 ) Equity in net income of consolidated subsidiaries 80,007 68,943 372 (149,322 ) — Income from continuing operations 56,540 69,817 79,384 (149,201 ) 56,540 Operating loss from discontinued operations (83 ) — — — (83 ) Tax benefit on loss from discontinued operations (67 ) — — — (67 ) Loss from discontinued operations (16 ) — — — (16 ) Net income 56,524 69,817 79,384 (149,201 ) 56,524 Other comprehensive income 17,253 14,107 16,947 (31,054 ) 17,253 Comprehensive income $ 73,777 $ 83,924 $ 96,331 $ (180,255 ) $ 73,777 Three Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed Consolidated (Dollars in thousands) Net revenues $ — $ 335,051 $ 303,676 $ (104,024 ) $ 534,703 Cost of goods sold — 194,262 149,302 (104,088 ) 239,476 Gross profit — 140,789 154,374 64 295,227 Selling, general and administrative expenses 10,536 89,315 64,046 (126 ) 163,771 Research and development expenses 220 14,788 6,186 — 21,194 Restructuring charges — 552 (644 ) — (92 ) (Loss) income from continuing operations before interest, extinguishment of debt and taxes (10,756 ) 36,134 84,786 190 110,354 Interest, net 29,231 (9,102 ) 849 — 20,978 (Loss) income from continuing operations before taxes (39,987 ) 45,236 83,937 190 89,376 (Benefit) taxes on (loss) income from continuing operations (21,968 ) 14,576 17,364 6 9,978 Equity in net income of consolidated subsidiaries 97,417 61,027 257 (158,701 ) — Income from continuing operations 79,398 91,687 66,830 (158,517 ) 79,398 Operating loss from discontinued operations (3,749 ) — — — (3,749 ) Tax benefit on loss from discontinued operations (1,366 ) — — — (1,366 ) Loss from discontinued operations (2,383 ) — — — (2,383 ) Net income 77,015 91,687 66,830 (158,517 ) 77,015 Other comprehensive income 43,845 30,196 56,286 (86,482 ) 43,845 Comprehensive income $ 120,860 $ 121,883 $ 123,116 $ (244,999 ) $ 120,860 Nine Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 1,169,684 $ 968,298 $ (331,214 ) $ 1,806,768 Cost of goods sold — 681,300 431,841 (324,994 ) 788,147 Gross profit — 488,384 536,457 (6,220 ) 1,018,621 Selling, general and administrative expenses 32,958 401,252 226,290 (352 ) 660,148 Research and development expenses 1,094 57,668 19,648 — 78,410 Restructuring and impairment charges — 20,581 57,044 — 77,625 (Loss) income from continuing operations before interest and taxes (34,052 ) 8,883 233,475 (5,868 ) 202,438 Interest, net 72,120 5,066 1,801 — 78,987 (Loss) income from continuing operations before taxes (106,172 ) 3,817 231,674 (5,868 ) 123,451 (Benefit) taxes on (loss) income from continuing operations (39,859 ) 11,347 44,134 (1,090 ) 14,532 Equity in net income of consolidated subsidiaries 176,511 170,276 1,007 (347,794 ) — Income from continuing operations 110,198 162,746 188,547 (352,572 ) 108,919 Operating (loss) income from discontinued operations (33 ) — 1,279 — 1,246 Tax benefit on loss from discontinued operations (47 ) — — — (47 ) Income from discontinued operations 14 — 1,279 — 1,293 Net income 110,212 162,746 189,826 (352,572 ) 110,212 Other comprehensive loss (24,076 ) (30,691 ) (26,551 ) 57,242 (24,076 ) Comprehensive income $ 86,136 $ 132,055 $ 163,275 $ (295,330 ) $ 86,136 Nine Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 989,314 $ 876,968 $ (315,085 ) $ 1,551,197 Cost of goods sold — 576,465 445,638 (311,977 ) 710,126 Gross profit — 412,849 431,330 (3,108 ) 841,071 Selling, general and administrative expenses 38,523 278,529 169,224 398 486,674 Research and development expenses 719 39,568 19,012 — 59,299 Restructuring charges — 7,261 6,462 — 13,723 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (39,242 ) 87,491 236,632 (3,506 ) 281,375 Interest, net 80,737 (25,245 ) 2,776 — 58,268 Loss on extinguishment of debt 5,593 — — — 5,593 (Loss) income from continuing operations before taxes (125,572 ) 112,736 233,856 (3,506 ) 217,514 (Benefit) taxes on (loss) income from continuing operations (57,679 ) 33,873 43,803 (593 ) 19,404 Equity in net income of consolidated subsidiaries 266,003 175,690 713 (442,406 ) — Income from continuing operations 198,110 254,553 190,766 (445,319 ) 198,110 Operating loss from discontinued operations (4,597 ) — — — (4,597 ) Tax benefit on loss from discontinued operations (1,675 ) — — — (1,675 ) Loss from discontinued operations (2,922 ) — — — (2,922 ) Net income 195,188 254,553 190,766 (445,319 ) 195,188 Other comprehensive income 163,267 147,727 179,561 (327,288 ) 163,267 Comprehensive income $ 358,455 $ 402,280 $ 370,327 $ (772,607 ) $ 358,455 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 47,766 $ 1,288 $ 307,222 $ — $ 356,276 Accounts receivable, net 2,932 55,452 310,942 5,015 374,341 Accounts receivable from consolidated subsidiaries 24,606 994,236 351,740 (1,370,582 ) — Inventories, net — 245,600 197,784 (32,318 ) 411,066 Prepaid expenses and other current assets 14,379 12,409 24,403 3,982 55,173 Prepaid taxes 33,766 — 6,949 — 40,715 Assets held for sale — 3,239 — — 3,239 Total current assets 123,449 1,312,224 1,199,040 (1,393,903 ) 1,240,810 Property, plant and equipment, net 3,177 238,079 180,009 — 421,265 Goodwill — 1,245,455 977,974 — 2,223,429 Intangibles assets, net 95 1,274,994 987,729 — 2,262,818 Investments in consolidated subsidiaries 5,929,366 1,673,596 20,625 (7,623,587 ) — Deferred tax assets — — 4,589 (2,284 ) 2,305 Notes receivable and other amounts due from consolidated subsidiaries 2,265,457 2,445,390 — (4,710,847 ) — Other assets 30,226 6,057 13,810 — 50,093 Total assets $ 8,351,770 $ 8,195,795 $ 3,383,776 $ (13,730,621 ) $ 6,200,720 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 27,250 $ — $ 50,000 $ — $ 77,250 Accounts payable 4,254 54,791 38,583 — 97,628 Accounts payable to consolidated subsidiaries 1,024,109 280,381 66,092 (1,370,582 ) — Accrued expenses 17,966 36,206 51,412 — 105,584 Current portion of contingent consideration — 101,573 1,091 — 102,664 Payroll and benefit-related liabilities 18,184 31,405 44,543 — 94,132 Accrued interest 20,595 — 28 — 20,623 Income taxes payable — — 14,437 (1,090 ) 13,347 Other current liabilities 1,637 33,589 2,839 — 38,065 Total current liabilities 1,113,995 537,945 269,025 (1,371,672 ) 549,293 Long-term borrowings 2,075,834 — — — 2,075,834 Deferred tax liabilities 92,270 264,288 251,808 (2,284 ) 606,082 Pension and postretirement benefit liabilities 49,853 32,019 17,478 — 99,350 Noncurrent liability for uncertain tax positions 1,986 8,352 2,832 — 13,170 Notes payable and other amounts due to consolidated subsidiaries 2,370,469 2,135,450 204,928 (4,710,847 ) — Noncurrent contingent consideration — 131,578 10,332 — 141,910 Other liabilities 140,298 9,026 58,692 — 208,016 Total liabilities 5,844,705 3,118,658 815,095 (6,084,803 ) 3,693,655 Total shareholders' equity 2,507,065 5,077,137 2,568,681 (7,645,818 ) 2,507,065 Total liabilities and shareholders' equity $ 8,351,770 $ 8,195,795 $ 3,383,776 $ (13,730,621 ) $ 6,200,720 December 31, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 37,803 $ 8,933 $ 286,822 $ — $ 333,558 Accounts receivable, net 2,414 57,818 280,980 4,663 345,875 Accounts receivable from consolidated subsidiaries 14,478 1,177,246 343,115 (1,534,839 ) — Inventories, net — 245,533 176,490 (26,279 ) 395,744 Prepaid expenses and other current assets 14,874 9,236 19,790 3,982 47,882 Prepaid taxes — — 5,748 — 5,748 Total current assets 69,569 1,498,766 1,112,945 (1,552,473 ) 1,128,807 Property, plant and equipment, net 2,088 213,663 167,248 — 382,999 Goodwill — 1,246,144 989,448 — 2,235,592 Intangibles assets, net — 1,355,275 1,028,473 — 2,383,748 Investments in consolidated subsidiaries 5,806,244 1,674,077 19,620 (7,499,941 ) — Deferred tax assets — — 6,071 (2,261 ) 3,810 Notes receivable and other amounts due from consolidated subsidiaries 2,452,101 2,231,832 — (4,683,933 ) — Other assets 31,173 6,397 8,966 — 46,536 Total assets $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 36,625 $ — $ 50,000 $ — $ 86,625 Accounts payable 4,269 46,992 40,766 — 92,027 Accounts payable to consolidated subsidiaries 1,211,568 261,121 62,150 (1,534,839 ) — Accrued expenses 17,957 31,827 47,069 — 96,853 Current portion of contingent consideration — 74,224 — — 74,224 Payroll and benefit-related liabilities 21,145 44,009 42,261 — 107,415 Accrued interest 6,133 — 32 — 6,165 Income taxes payable 4,352 — 7,162 — 11,514 Other current liabilities 1,461 3,775 3,817 — 9,053 Total current liabilities 1,303,510 461,948 253,257 (1,534,839 ) 483,876 Long-term borrowings 2,162,927 — — — 2,162,927 Deferred tax liabilities 88,512 265,426 251,999 (2,261 ) 603,676 Pension and postretirement benefit liabilities 70,860 32,750 17,800 — 121,410 Noncurrent liability for uncertain tax positions 1,117 8,196 2,983 — 12,296 Notes payable and other amounts due to consolidated subsidiaries 2,155,146 2,320,611 208,176 (4,683,933 ) — Noncurrent contingent consideration — 186,923 10,989 — 197,912 Other liabilities 148,572 7,850 12,442 — 168,864 Total liabilities 5,930,644 3,283,704 757,646 (6,221,033 ) 3,750,961 Total shareholders' equity 2,430,531 4,942,450 2,575,125 (7,517,575 ) 2,430,531 Total liabilities and shareholders' equity $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Nine Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (202,209 ) $ 382,389 $ 268,390 $ (145,626 ) $ 302,944 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (1,524 ) (23,686 ) (30,541 ) — (55,751 ) Proceeds from sale of investments 28,239 — — (28,239 ) — Payments for businesses and intangibles acquired, net of cash acquired (100 ) 1,404 (23,854 ) — (22,550 ) Net cash provided by (used in) investing activities from continuing operations 26,615 (22,282 ) (54,395 ) (28,239 ) (78,301 ) Cash flows from financing activities of continuing operations: Reduction in borrowings (98,500 ) — — — (98,500 ) Debt extinguishment, issuance and amendment fees (188 ) — — — (188 ) Net proceeds from share based compensation plans and the related tax impacts 18,666 — — — 18,666 Payments for contingent consideration — (73,152 ) — — (73,152 ) Dividends paid (46,526 ) — — — (46,526 ) Intercompany transactions 312,806 (294,600 ) (46,445 ) 28,239 — Intercompany dividends paid — — (145,626 ) 145,626 — Net cash provided by (used in) financing activities from continuing operations 186,258 (367,752 ) (192,071 ) 173,865 (199,700 ) Cash flows from discontinued operations: Net cash used in operating activities (701 ) — — — (701 ) Net cash used in discontinued operations (701 ) — — — (701 ) Effect of exchange rate changes on cash and cash equivalents — — (1,524 ) — (1,524 ) Net increase (decrease) in cash and cash equivalents 9,963 (7,645 ) 20,400 — 22,718 Cash and cash equivalents at the beginning of the period 37,803 8,933 286,822 — 333,558 Cash and cash equivalents at the end of the period $ 47,766 $ 1,288 $ 307,222 $ — $ 356,276 Nine Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (156,643 ) $ 300,961 $ 237,308 $ (61,918 ) $ 319,708 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (233 ) (27,527 ) (26,217 ) — (53,977 ) Proceeds from sale of assets 464,982 — 6,332 (464,982 ) 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — (35,187 ) — (1,010,711 ) Net cash used in investing activities from continuing operations (510,775 ) (27,527 ) (55,072 ) (464,982 ) (1,058,356 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,963,500 — — — 1,963,500 Reduction in borrowings (747,576 ) — — — (747,576 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts 4,739 — — — 4,739 Payments for contingent consideration — (245 ) — — (245 ) Dividends paid (45,905 ) — — — (45,905 ) Intercompany transactions (456,468 ) 474,192 (482,706 ) 464,982 — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 699,176 473,947 (544,624 ) 526,900 1,155,399 Cash flows from discontinued operations: Net cash used in operating activities (1,140 ) — — — (1,140 ) Net cash used in discontinued operations (1,140 ) — — — (1,140 ) Effect of exchange rate changes on cash and cash equivalents — — 58,173 — 58,173 Net increase (decrease) in cash and cash equivalents 30,618 747,381 (304,215 ) — 473,784 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 45,189 $ 748,412 $ 223,972 $ — $ 1,017,573

Subsequent events

Subsequent events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent events	Subsequent events Cross-currency interest rate swap On October 4, 2018, the Company entered into cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, the Company has notionally exchanged $500 million at an annual interest rate of 4.625% for €433.9 million at an annual interest rate of 1.942% . The swap agreements are designated as net investment hedges and expire on October 4, 2023. Essential Medical, Inc. acquisition On October 4, 2018, the Company acquired Essential Medical, Inc. ("Essential Medical"), a medical device company that developed the CE marked MANTA Vascular Closure Device, which is designed for closure of large bore arteriotomies and complements the Company's interventional product portfolio. Under the terms of the acquisition agreement, the Company acquired Essential Medical for an initial purchase price of $60 million in cash, subject to customary purchase price adjustments. The agreement also provides for additional payments of up to $100 million if certain sales and regulatory goals are met.

New accounting standards (Polic

New accounting standards (Policies)	9 Months Ended
	Sep. 30, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, as amended by additional guidance issued in 2015 and 2016, is encompassed in FASB Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”) and is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and affects any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The Company adopted the new standard on January 1, 2018, applying the modified retrospective method to all of its contracts; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.2 million increase to the Company's opening balance of retained earnings on the adoption date. In addition, in connection with its adoption of the new guidance, the Company reclassified the reserve for product returns from a reduction of receivables to a liability. The reserve for returns and allowances was $4.6 million at September 30, 2018 . The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. Additional information and disclosures required by this new standard are contained in Note 3. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases, subject to an option to elect certain practical expedients. As a result, companies can elect to apply the transition approach either for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements or for leases existing at, or entered into after, the adoption date. The Company is currently evaluating this guidance to determine its impact on the Company’s consolidated results of operations, cash flows and financial position. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The Company adopted the new standard on January 1, 2018 using the modified retrospective method of adoption; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.8 million increase to the Company's opening balance of retained earnings on the adoption date. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. In March 2017, the FASB issued guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. The Company adopted this guidance on January 1, 2018; the impact was not material to the consolidated financial statements. In August 2017, the FASB issued guidance with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The new guidance provides for changes to current designation and measurement guidance for qualifying hedging relationships and to the method of presenting hedge results. In addition, the new guidance includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The new guidance is effective for reporting periods beginning after December 15, 2018, but the guidance permits early adoptions, and the Company adopted the guidance effective October 1, 2018; the adoption did not result in any cumulative-effect adjustments to retained earnings. In February 2018, the FASB issued new guidance to address a narrow-scope financial reporting issue that arose as a consequence of the Tax Cuts and Jobs Act ("the TCJA"). Existing guidance requires that deferred tax liabilities and assets be adjusted for a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The guidance is applicable even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in net income), such as amounts related to benefit plans and hedging activity. As a result, the tax effects of items within accumulated other comprehensive income (referred to as stranded tax effects) do not reflect the appropriate tax rate. The new guidance permits a reclassification of these amounts from accumulated other comprehensive income to retained earnings, thereby eliminating the stranded tax effects. The new guidance also requires certain disclosures about the stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The new guidance can be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate under the TCJA is recognized. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.

Net revenues (Tables)

Net revenues (Tables)	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The following table disaggregates revenue by global product category for the three and nine months ended September 30, 2018 and October 1, 2017 . Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 Revenue by global product category (1) (2) (Dollars in thousands) Vascular access $ 142,712 $ 133,521 $ 427,557 $ 396,866 Anesthesia 87,973 87,964 263,202 255,107 Interventional 79,404 69,186 228,262 181,577 Surgical 89,910 85,210 266,049 263,254 Interventional urology 48,995 — 138,969 — OEM 54,838 48,589 153,286 137,067 Other (3) 105,840 110,233 329,443 317,326 Net revenues $ 609,672 $ 534,703 $ 1,806,768 $ 1,551,197 (1) The product categories listed above are presented on a global basis; in contrast, the Company’s North American reportable segments generally are defined largely based on the particular products sold by the segments, and its non-North American reportable segments are defined exclusively based on the geographic location of segment operations (with the exception of the Original Equipment and Development Services ("OEM") reportable segment, which operates globally). The Company’s EMEA and Asia reportable segments, as well as its Latin America operating segment, include net revenues from each of the product categories listed above. (2) The methodology used to determine the product revenues included within certain of the product categories listed in the table above differs from the methodology used to classify revenues in our reportable segments, including the similarly named North American reportable segments. The differences are due to the fact that segment classification generally is determined based on the call point within the customer's organization from which the purchase order resulting in the sale originated, while the classification of products within the product categories listed in the table above includes all sales of products within the listed product category, regardless of the call point within the customer's organization from which the sale originated. (3) Other revenues in the table above include revenues related to sales of the Company’s respiratory, urology and cardiac products.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information	The following unaudited pro forma combined financial information for the three and nine months ended October 1, 2017 gives effect to the Vascular Solutions and NeoTract acquisitions as if they had occurred on January 1, 2016. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. Three Months Ended Nine Months Ended October 1, 2017 October 1, 2017 (Dollars and shares in thousands, except per share) Net revenue $ 568,437 $ 1,660,591 Net income $ 52,909 $ 157,249 Basic earnings per common share: Net income $ 1.17 $ 3.50 Diluted earnings per common share: Net income $ 1.14 $ 3.37 Weighted average common shares outstanding: Basic 45,035 44,975 Diluted 46,587 46,673

Restructuring charges and imp_2

Restructuring charges and impairment charges (Tables)	9 Months Ended
	Sep. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Other Impairment Charges	Restructuring charges (credits) by reportable operating segment, and by all other operating segments in the aggregate, for the three and nine months ended September 30, 2018 and October 1, 2017 are set forth in the following table: Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) Vascular North America $ 203 $ 582 $ 725 $ 1,663 Interventional North America (26 ) (228 ) 881 4,178 Anesthesia North America 38 220 164 1,031 EMEA 1,520 (632 ) 54,310 6,483 All other 229 (34 ) 2,435 368 Restructuring charges $ 1,964 $ (92 ) $ 58,515 $ 13,723 The following tables provide information regarding restructuring and impairment charges (credits) recognized by the Company for the three and nine months ended September 30, 2018 and October 1, 2017 : Three Months Ended September 30, 2018 Termination benefits Other costs (1) Total (Dollars in thousands) 2018 Footprint realignment plan $ 1,119 $ 145 $ 1,264 Other restructuring programs (2) 468 232 700 Restructuring charges $ 1,587 $ 377 $ 1,964 Asset impairment charges — 17,245 17,245 Restructuring and impairment charges $ 1,587 $ 17,622 $ 19,209 Three Months Ended October 1, 2017 Termination benefits Other costs (1) Total (Dollars in thousands) Restructuring (credits) charges (3) $ (554 ) $ 462 $ (92 ) Nine Months Ended September 30, 2018 Termination benefits Other costs (1) Total (Dollars in thousands) 2018 Footprint realignment plan $ 53,463 $ 275 $ 53,738 2016 Footprint realignment plan 2,379 417 2,796 Other restructuring programs (4) 1,318 663 1,981 Restructuring charges $ 57,160 $ 1,355 $ 58,515 Asset impairment charges — 19,110 19,110 Restructuring and impairment charges $ 57,160 $ 20,465 $ 77,625 Nine Months Ended October 1, 2017 Termination benefits Other costs (1) Total (Dollars in thousands) 2017 Vascular Solutions integration program $ 4,534 $ 92 $ 4,626 2017 EMEA restructuring program 5,822 84 5,906 2016 Footprint realignment plan 1,099 233 1,332 Other restructuring programs (5) 1,352 507 1,859 Restructuring charges $ 12,807 $ 916 $ 13,723 (1) Other costs include facility closure, contract termination, and other exit costs. (2) Other restructuring programs include the 2016 and 2014 Footprint realignment plans, the 2017 Vascular Solutions integration program, the 2017 EMEA restructuring program and the other 2016 restructuring programs. (3) Restructuring charges (credits) include activity related to the 2017 Vascular Solutions integration program, the 2017 EMEA restructuring program, the 2016 and 2014 footprint realignment plans, the 2017 Pyng integration program and the other 2016 restructuring programs. The Company committed to the 2017 Pyng integration program, which relates to the integration of Pyng Medical Corp. (“Pyng”) into the Company, during the second quarter of 2017, following the Company’s acquisition of Pyng in April 2017. (4) Other restructuring programs include the 2014 Footprint realignment plan, the 2017 Vascular Solutions integration program, the 2017 EMEA restructuring program and the other 2016 restructuring programs. (5) Other restructuring programs include the 2014 Footprint realignment plan, the 2017 Pyng integration program and the other 2016 restructuring programs.
Summary Of Current Cost Estimates By Major Type Of Cost Table	The following table provides a summary of the Company’s cost estimates by major type of expense associated with the 2018 Footprint realignment plan: Type of expense Total estimated amount expected to be incurred Termination benefits $60 million to $70 million Other exit costs (1) $2 million to $4 million Restructuring charges $62 million to $74 million Restructuring related charges (2) $40 million to $59 million Total restructuring and restructuring related charges $102 million to $133 million (1) Includes contract termination, facility closure, employee relocation, equipment relocation and outplacement costs. (2) Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to transfer manufacturing operations to the new locations, as well as a charge associated with the Company’s exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the charges are expected to be recognized within costs of goods sold.

Inventories, net (Tables)

Inventories, net (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventories, net	Inventories as of September 30, 2018 and December 31, 2017 consisted of the following: September 30, 2018 December 31, 2017 (Dollars in thousands) Raw materials $ 105,600 $ 98,451 Work-in-process 65,291 62,381 Finished goods 240,175 234,912 Inventories, net $ 411,066 $ 395,744

Goodwill and other intangible_2

Goodwill and other intangible assets, net (Tables)	9 Months Ended
	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment, and by all other operating segments in the aggregate, for the nine months ended September 30, 2018 : Vascular Interventional North America Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) December 31, 2017 $ 264,869 $ 433,049 $ 157,289 $ 250,912 $ 494,548 $ 209,200 $ 4,883 $ 420,842 $ 2,235,592 Goodwill related to acquisitions — 1,027 — — (27 ) (9 ) — (413 ) 578 Currency translation adjustment — (1,934 ) (634 ) — (7,778 ) (3,079 ) — 684 (12,741 ) September 30, 2018 $ 264,869 $ 432,142 $ 156,655 $ 250,912 $ 486,743 $ 206,112 $ 4,883 $ 421,113 $ 2,223,429
Schedule of Finite-Lived Intangible Assets	The Company's gross carrying amount of, and accumulated amortization relating to, intangible assets as of September 30, 2018 and December 31, 2017 were as follows: Gross Carrying Amount Accumulated Amortization September 30, 2018 December 31, 2017 September 30, 2018 December 31, 2017 (Dollars in thousands) Customer relationships $ 1,020,603 $ 1,023,837 $ (314,051 ) $ (281,263 ) In-process research and development 29,377 34,672 — — Intellectual property 1,273,503 1,287,487 (305,350 ) (258,580 ) Distribution rights 23,637 23,697 (17,756 ) (16,996 ) Trade names 569,570 571,510 (33,001 ) (22,069 ) Non-compete agreements 23,672 23,429 (7,386 ) (1,976 ) $ 2,940,362 $ 2,964,632 $ (677,544 ) $ (580,884 )

Financial instruments (Tables)

Financial instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values of Derivative Instruments Designated as Hedging Instruments	The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of September 30, 2018 and December 31, 2017 : September 30, 2018 December 31, 2017 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 2,158 $ 914 Non-designated foreign currency forward contracts 175 307 Prepaid expenses and other current assets $ 2,333 $ 1,221 Total asset derivatives $ 2,333 $ 1,221 Liability derivatives: Designated foreign currency forward contracts $ 572 $ 1,373 Non-designated foreign currency forward contracts 1,064 53 Other current liabilities $ 1,636 $ 1,426 Total liability derivatives $ 1,636 $ 1,426
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at September 30, 2018 and December 31, 2017 : September 30, 2018 December 31, 2017 (Dollars in thousands) Allowance for doubtful accounts (1) $ 9,657 $ 10,255 Current and long-term trade accounts receivable, net in Greece, Italy, Spain and Portugal (2) $ 51,468 $ 49,054 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 14.1 % 14.6 % (1) The current portion of the allowance for doubtful accounts was $3.9 million and $3.5 million as of September 30, 2018 and December 31, 2017 , respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at September 30, 2018 and December 31, 2017 was $4.2 million and $3.3 million , respectively.

Fair value measurement (Tables)

Fair value measurement (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 9,849 $ 9,849 $ — $ — Derivative assets 2,333 — 2,333 — Derivative liabilities 1,636 — 1,636 — Contingent consideration liabilities 244,574 — — 244,574 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 9,045 $ 9,045 $ — $ — Derivative assets 1,221 — 1,221 — Derivative liabilities 1,426 — 1,426 — Contingent consideration liabilities 272,136 — — 272,136
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration recognized in connection with the NeoTract acquisition. Valuation Technique Unobservable Input Range Contingent consideration Monte Carlo simulation Revenue volatility 24.1 % Risk free rate Cost of debt structure Projected year of payment 2019 - 2021
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes, during the nine months ended September 30, 2018 , in Level 3 financial liabilities related to contingent consideration: Contingent consideration 2018 (Dollars in thousands) Balance - December 31, 2017 $ 272,136 Additions (1) 396 Payments (2) (75,252 ) Revaluations 47,344 Translation adjustment (50 ) Balance - September 30, 2018 $ 244,574 (1) The Company established a liability related to the estimated fair value of contingent consideration associated with the acquired assets from QT Vascular. (2) Consists mainly of a $75.0 million payment resulting from the achievement of a sales goal associated with the NeoTract acquisition for the period from January 1, 2018 to April 30, 2018.

Shareholders' equity (Tables)

Shareholders' equity (Tables)	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Shares in thousands) Basic 45,851 45,035 45,587 44,975 Dilutive effect of share-based awards 919 934 1,007 873 Dilutive effect of convertible notes and warrants 45 618 191 825 Diluted 46,815 46,587 46,785 46,673
Change in Accumulated Other Comprehensive Income (Loss)	The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2018 and October 1, 2017 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2017 $ 340 $ (138,808 ) $ (126,623 ) $ (265,091 ) Other comprehensive income (loss) before reclassifications 2,816 127 (30,130 ) (27,187 ) Amounts reclassified from accumulated other comprehensive income (873 ) 3,984 — 3,111 Net current-period other comprehensive income (loss) 1,943 4,111 (30,130 ) (24,076 ) Balance as of September 30, 2018 $ 2,283 $ (134,697 ) $ (156,753 ) $ (289,167 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive (loss) before reclassifications 3,383 (1,050 ) 156,012 158,345 Amounts reclassified from accumulated other comprehensive loss 1,535 3,387 — 4,922 Net current-period other comprehensive income 4,918 2,337 156,012 163,267 Balance as of October 1, 2017 $ 2,494 $ (134,259 ) $ (143,685 ) $ (275,450 )
Reclassification of Gain/Losses into Income/Expense, Net of Tax	The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and nine months ended September 30, 2018 and October 1, 2017 : Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ (87 ) $ (1,179 ) $ (1,038 ) $ 1,769 Total before tax (87 ) (1,179 ) (1,038 ) 1,769 Taxes (benefit) 25 237 165 (234 ) Net of tax $ (62 ) $ (942 ) $ (873 ) $ 1,535 Amortization of pension and other postretirement benefit items (1): Actuarial losses $ 1,640 $ 1,723 $ 5,120 $ 5,176 Prior-service costs 24 20 71 79 Total before tax 1,664 1,743 5,191 5,255 Tax benefit (388 ) (619 ) (1,207 ) (1,868 ) Net of tax $ 1,276 $ 1,124 $ 3,984 $ 3,387 Total reclassifications, net of tax $ 1,214 $ 182 $ 3,111 $ 4,922 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continui_2

Taxes on income from continuing operations (Tables)	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 Effective income tax rate (2.3)% 11.2% 11.8% 8.9%

Pension and other postretirem_2

Pension and other postretirement benefits (Tables)	9 Months Ended
	Sep. 30, 2018
Retirement Benefits [Abstract]
Schedule of Net Benefit Cost of Pension and Postretirement Benefit Plans	Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits Pension Other Postretirement Benefits September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) Service cost $ 380 $ 725 $ (66 ) $ 61 $ 1,135 $ 2,162 $ 38 $ 210 Interest cost 3,681 3,773 285 426 11,119 11,347 1,042 1,183 Expected return on plan assets (7,423 ) (6,607 ) — — (22,260 ) (20,100 ) — — Net amortization and deferral 1,687 1,668 (23 ) 75 5,090 5,049 101 206 Net benefits expense (income) $ (1,675 ) $ (441 ) $ 196 $ 562 $ (4,916 ) $ (1,542 ) $ 1,181 $ 1,599

Segment information (Tables)

Segment information (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Results	The following tables present the Company’s segment results for the three and nine months ended September 30, 2018 and October 1, 2017 : Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) Vascular North America $ 80,719 $ 75,065 $ 243,829 $ 232,872 Interventional North America 66,726 60,719 191,878 159,002 Anesthesia North America 53,160 50,819 154,215 148,107 Surgical North America 42,545 40,804 123,930 131,464 EMEA 139,541 137,034 452,826 409,077 Asia 76,544 74,202 207,201 190,368 OEM 54,838 48,589 153,286 137,067 All other 95,599 47,471 279,603 143,240 Net revenues $ 609,672 $ 534,703 $ 1,806,768 $ 1,551,197 Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) Vascular North America $ 24,287 $ 17,803 $ 73,585 $ 54,565 Interventional North America 17,142 12,485 47,772 13,265 Anesthesia North America 16,811 15,084 48,860 48,444 Surgical North America 15,906 13,618 47,709 47,285 EMEA 21,916 24,198 80,221 69,102 Asia 20,834 20,427 54,948 50,252 OEM 15,049 12,256 37,617 31,714 All other (5,587 ) 7,290 (43,162 ) 25,634 Total segment operating profit (1) 126,358 123,161 347,550 340,261 Unallocated expenses (2) (44,253 ) (12,807 ) (145,112 ) (58,886 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 82,105 $ 110,354 $ 202,438 $ 281,375 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.
Schedule Of Revenues By Geographic Region Table	The following table provides total net revenues by geographic region (based on the Company's selling location) for the three and nine months ended September 30, 2018 and October 1, 2017 : Three Months Ended Nine Months Ended September 30, 2018 October 1, 2017 September 30, 2018 October 1, 2017 (Dollars in thousands) United States $ 365,271 $ 306,763 $ 1,066,095 $ 903,201 Europe 160,498 148,808 500,697 434,223 Asia 60,414 59,169 170,458 156,074 All other 23,489 19,963 69,518 57,699 Net revenues $ 609,672 $ 534,703 $ 1,806,768 $ 1,551,197

Condensed consolidating guara_2

Condensed consolidating guarantor financial information (Tables)	9 Months Ended
	Sep. 30, 2018
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 398,961 $ 322,010 $ (111,299 ) $ 609,672 Cost of goods sold — 232,209 146,301 (111,411 ) 267,099 Gross profit — 166,752 175,709 112 342,573 Selling, general and administrative expenses 11,347 130,773 72,796 (22 ) 214,894 Research and development expenses 378 19,482 6,505 — 26,365 Restructuring charges — 17,128 2,081 — 19,209 (Loss) income from continuing operations before interest and taxes (11,725 ) (631 ) 94,327 134 82,105 Interest, net 25,191 1,057 603 — 26,851 (Loss) income from continuing operations before taxes (36,916 ) (1,688 ) 93,724 134 55,254 (Benefit) taxes on (loss) income from continuing operations (13,449 ) (2,562 ) 14,712 13 (1,286 ) Equity in net income of consolidated subsidiaries 80,007 68,943 372 (149,322 ) — Income from continuing operations 56,540 69,817 79,384 (149,201 ) 56,540 Operating loss from discontinued operations (83 ) — — — (83 ) Tax benefit on loss from discontinued operations (67 ) — — — (67 ) Loss from discontinued operations (16 ) — — — (16 ) Net income 56,524 69,817 79,384 (149,201 ) 56,524 Other comprehensive income 17,253 14,107 16,947 (31,054 ) 17,253 Comprehensive income $ 73,777 $ 83,924 $ 96,331 $ (180,255 ) $ 73,777 Three Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed Consolidated (Dollars in thousands) Net revenues $ — $ 335,051 $ 303,676 $ (104,024 ) $ 534,703 Cost of goods sold — 194,262 149,302 (104,088 ) 239,476 Gross profit — 140,789 154,374 64 295,227 Selling, general and administrative expenses 10,536 89,315 64,046 (126 ) 163,771 Research and development expenses 220 14,788 6,186 — 21,194 Restructuring charges — 552 (644 ) — (92 ) (Loss) income from continuing operations before interest, extinguishment of debt and taxes (10,756 ) 36,134 84,786 190 110,354 Interest, net 29,231 (9,102 ) 849 — 20,978 (Loss) income from continuing operations before taxes (39,987 ) 45,236 83,937 190 89,376 (Benefit) taxes on (loss) income from continuing operations (21,968 ) 14,576 17,364 6 9,978 Equity in net income of consolidated subsidiaries 97,417 61,027 257 (158,701 ) — Income from continuing operations 79,398 91,687 66,830 (158,517 ) 79,398 Operating loss from discontinued operations (3,749 ) — — — (3,749 ) Tax benefit on loss from discontinued operations (1,366 ) — — — (1,366 ) Loss from discontinued operations (2,383 ) — — — (2,383 ) Net income 77,015 91,687 66,830 (158,517 ) 77,015 Other comprehensive income 43,845 30,196 56,286 (86,482 ) 43,845 Comprehensive income $ 120,860 $ 121,883 $ 123,116 $ (244,999 ) $ 120,860 Nine Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 1,169,684 $ 968,298 $ (331,214 ) $ 1,806,768 Cost of goods sold — 681,300 431,841 (324,994 ) 788,147 Gross profit — 488,384 536,457 (6,220 ) 1,018,621 Selling, general and administrative expenses 32,958 401,252 226,290 (352 ) 660,148 Research and development expenses 1,094 57,668 19,648 — 78,410 Restructuring and impairment charges — 20,581 57,044 — 77,625 (Loss) income from continuing operations before interest and taxes (34,052 ) 8,883 233,475 (5,868 ) 202,438 Interest, net 72,120 5,066 1,801 — 78,987 (Loss) income from continuing operations before taxes (106,172 ) 3,817 231,674 (5,868 ) 123,451 (Benefit) taxes on (loss) income from continuing operations (39,859 ) 11,347 44,134 (1,090 ) 14,532 Equity in net income of consolidated subsidiaries 176,511 170,276 1,007 (347,794 ) — Income from continuing operations 110,198 162,746 188,547 (352,572 ) 108,919 Operating (loss) income from discontinued operations (33 ) — 1,279 — 1,246 Tax benefit on loss from discontinued operations (47 ) — — — (47 ) Income from discontinued operations 14 — 1,279 — 1,293 Net income 110,212 162,746 189,826 (352,572 ) 110,212 Other comprehensive loss (24,076 ) (30,691 ) (26,551 ) 57,242 (24,076 ) Comprehensive income $ 86,136 $ 132,055 $ 163,275 $ (295,330 ) $ 86,136 Nine Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 989,314 $ 876,968 $ (315,085 ) $ 1,551,197 Cost of goods sold — 576,465 445,638 (311,977 ) 710,126 Gross profit — 412,849 431,330 (3,108 ) 841,071 Selling, general and administrative expenses 38,523 278,529 169,224 398 486,674 Research and development expenses 719 39,568 19,012 — 59,299 Restructuring charges — 7,261 6,462 — 13,723 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (39,242 ) 87,491 236,632 (3,506 ) 281,375 Interest, net 80,737 (25,245 ) 2,776 — 58,268 Loss on extinguishment of debt 5,593 — — — 5,593 (Loss) income from continuing operations before taxes (125,572 ) 112,736 233,856 (3,506 ) 217,514 (Benefit) taxes on (loss) income from continuing operations (57,679 ) 33,873 43,803 (593 ) 19,404 Equity in net income of consolidated subsidiaries 266,003 175,690 713 (442,406 ) — Income from continuing operations 198,110 254,553 190,766 (445,319 ) 198,110 Operating loss from discontinued operations (4,597 ) — — — (4,597 ) Tax benefit on loss from discontinued operations (1,675 ) — — — (1,675 ) Loss from discontinued operations (2,922 ) — — — (2,922 ) Net income 195,188 254,553 190,766 (445,319 ) 195,188 Other comprehensive income 163,267 147,727 179,561 (327,288 ) 163,267 Comprehensive income $ 358,455 $ 402,280 $ 370,327 $ (772,607 ) $ 358,455
Condensed Consolidating Balance Sheets	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 47,766 $ 1,288 $ 307,222 $ — $ 356,276 Accounts receivable, net 2,932 55,452 310,942 5,015 374,341 Accounts receivable from consolidated subsidiaries 24,606 994,236 351,740 (1,370,582 ) — Inventories, net — 245,600 197,784 (32,318 ) 411,066 Prepaid expenses and other current assets 14,379 12,409 24,403 3,982 55,173 Prepaid taxes 33,766 — 6,949 — 40,715 Assets held for sale — 3,239 — — 3,239 Total current assets 123,449 1,312,224 1,199,040 (1,393,903 ) 1,240,810 Property, plant and equipment, net 3,177 238,079 180,009 — 421,265 Goodwill — 1,245,455 977,974 — 2,223,429 Intangibles assets, net 95 1,274,994 987,729 — 2,262,818 Investments in consolidated subsidiaries 5,929,366 1,673,596 20,625 (7,623,587 ) — Deferred tax assets — — 4,589 (2,284 ) 2,305 Notes receivable and other amounts due from consolidated subsidiaries 2,265,457 2,445,390 — (4,710,847 ) — Other assets 30,226 6,057 13,810 — 50,093 Total assets $ 8,351,770 $ 8,195,795 $ 3,383,776 $ (13,730,621 ) $ 6,200,720 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 27,250 $ — $ 50,000 $ — $ 77,250 Accounts payable 4,254 54,791 38,583 — 97,628 Accounts payable to consolidated subsidiaries 1,024,109 280,381 66,092 (1,370,582 ) — Accrued expenses 17,966 36,206 51,412 — 105,584 Current portion of contingent consideration — 101,573 1,091 — 102,664 Payroll and benefit-related liabilities 18,184 31,405 44,543 — 94,132 Accrued interest 20,595 — 28 — 20,623 Income taxes payable — — 14,437 (1,090 ) 13,347 Other current liabilities 1,637 33,589 2,839 — 38,065 Total current liabilities 1,113,995 537,945 269,025 (1,371,672 ) 549,293 Long-term borrowings 2,075,834 — — — 2,075,834 Deferred tax liabilities 92,270 264,288 251,808 (2,284 ) 606,082 Pension and postretirement benefit liabilities 49,853 32,019 17,478 — 99,350 Noncurrent liability for uncertain tax positions 1,986 8,352 2,832 — 13,170 Notes payable and other amounts due to consolidated subsidiaries 2,370,469 2,135,450 204,928 (4,710,847 ) — Noncurrent contingent consideration — 131,578 10,332 — 141,910 Other liabilities 140,298 9,026 58,692 — 208,016 Total liabilities 5,844,705 3,118,658 815,095 (6,084,803 ) 3,693,655 Total shareholders' equity 2,507,065 5,077,137 2,568,681 (7,645,818 ) 2,507,065 Total liabilities and shareholders' equity $ 8,351,770 $ 8,195,795 $ 3,383,776 $ (13,730,621 ) $ 6,200,720 December 31, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 37,803 $ 8,933 $ 286,822 $ — $ 333,558 Accounts receivable, net 2,414 57,818 280,980 4,663 345,875 Accounts receivable from consolidated subsidiaries 14,478 1,177,246 343,115 (1,534,839 ) — Inventories, net — 245,533 176,490 (26,279 ) 395,744 Prepaid expenses and other current assets 14,874 9,236 19,790 3,982 47,882 Prepaid taxes — — 5,748 — 5,748 Total current assets 69,569 1,498,766 1,112,945 (1,552,473 ) 1,128,807 Property, plant and equipment, net 2,088 213,663 167,248 — 382,999 Goodwill — 1,246,144 989,448 — 2,235,592 Intangibles assets, net — 1,355,275 1,028,473 — 2,383,748 Investments in consolidated subsidiaries 5,806,244 1,674,077 19,620 (7,499,941 ) — Deferred tax assets — — 6,071 (2,261 ) 3,810 Notes receivable and other amounts due from consolidated subsidiaries 2,452,101 2,231,832 — (4,683,933 ) — Other assets 31,173 6,397 8,966 — 46,536 Total assets $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 36,625 $ — $ 50,000 $ — $ 86,625 Accounts payable 4,269 46,992 40,766 — 92,027 Accounts payable to consolidated subsidiaries 1,211,568 261,121 62,150 (1,534,839 ) — Accrued expenses 17,957 31,827 47,069 — 96,853 Current portion of contingent consideration — 74,224 — — 74,224 Payroll and benefit-related liabilities 21,145 44,009 42,261 — 107,415 Accrued interest 6,133 — 32 — 6,165 Income taxes payable 4,352 — 7,162 — 11,514 Other current liabilities 1,461 3,775 3,817 — 9,053 Total current liabilities 1,303,510 461,948 253,257 (1,534,839 ) 483,876 Long-term borrowings 2,162,927 — — — 2,162,927 Deferred tax liabilities 88,512 265,426 251,999 (2,261 ) 603,676 Pension and postretirement benefit liabilities 70,860 32,750 17,800 — 121,410 Noncurrent liability for uncertain tax positions 1,117 8,196 2,983 — 12,296 Notes payable and other amounts due to consolidated subsidiaries 2,155,146 2,320,611 208,176 (4,683,933 ) — Noncurrent contingent consideration — 186,923 10,989 — 197,912 Other liabilities 148,572 7,850 12,442 — 168,864 Total liabilities 5,930,644 3,283,704 757,646 (6,221,033 ) 3,750,961 Total shareholders' equity 2,430,531 4,942,450 2,575,125 (7,517,575 ) 2,430,531 Total liabilities and shareholders' equity $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492
Condensed Consolidating Statements of Cash Flows	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Nine Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (202,209 ) $ 382,389 $ 268,390 $ (145,626 ) $ 302,944 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (1,524 ) (23,686 ) (30,541 ) — (55,751 ) Proceeds from sale of investments 28,239 — — (28,239 ) — Payments for businesses and intangibles acquired, net of cash acquired (100 ) 1,404 (23,854 ) — (22,550 ) Net cash provided by (used in) investing activities from continuing operations 26,615 (22,282 ) (54,395 ) (28,239 ) (78,301 ) Cash flows from financing activities of continuing operations: Reduction in borrowings (98,500 ) — — — (98,500 ) Debt extinguishment, issuance and amendment fees (188 ) — — — (188 ) Net proceeds from share based compensation plans and the related tax impacts 18,666 — — — 18,666 Payments for contingent consideration — (73,152 ) — — (73,152 ) Dividends paid (46,526 ) — — — (46,526 ) Intercompany transactions 312,806 (294,600 ) (46,445 ) 28,239 — Intercompany dividends paid — — (145,626 ) 145,626 — Net cash provided by (used in) financing activities from continuing operations 186,258 (367,752 ) (192,071 ) 173,865 (199,700 ) Cash flows from discontinued operations: Net cash used in operating activities (701 ) — — — (701 ) Net cash used in discontinued operations (701 ) — — — (701 ) Effect of exchange rate changes on cash and cash equivalents — — (1,524 ) — (1,524 ) Net increase (decrease) in cash and cash equivalents 9,963 (7,645 ) 20,400 — 22,718 Cash and cash equivalents at the beginning of the period 37,803 8,933 286,822 — 333,558 Cash and cash equivalents at the end of the period $ 47,766 $ 1,288 $ 307,222 $ — $ 356,276 Nine Months Ended October 1, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (156,643 ) $ 300,961 $ 237,308 $ (61,918 ) $ 319,708 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (233 ) (27,527 ) (26,217 ) — (53,977 ) Proceeds from sale of assets 464,982 — 6,332 (464,982 ) 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — (35,187 ) — (1,010,711 ) Net cash used in investing activities from continuing operations (510,775 ) (27,527 ) (55,072 ) (464,982 ) (1,058,356 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,963,500 — — — 1,963,500 Reduction in borrowings (747,576 ) — — — (747,576 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts 4,739 — — — 4,739 Payments for contingent consideration — (245 ) — — (245 ) Dividends paid (45,905 ) — — — (45,905 ) Intercompany transactions (456,468 ) 474,192 (482,706 ) 464,982 — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 699,176 473,947 (544,624 ) 526,900 1,155,399 Cash flows from discontinued operations: Net cash used in operating activities (1,140 ) — — — (1,140 ) Net cash used in discontinued operations (1,140 ) — — — (1,140 ) Effect of exchange rate changes on cash and cash equivalents — — 58,173 — 58,173 Net increase (decrease) in cash and cash equivalents 30,618 747,381 (304,215 ) — 473,784 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 45,189 $ 748,412 $ 223,972 $ — $ 1,017,573

New accounting standards (Detai

New accounting standards (Details) - USD ($) $ in Millions	Sep. 30, 2018	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contract with customer, reverse for returns and allowances	$ 4.6
Accounting Standards Update 2016-16 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of change on equity		$ 1.8
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings (Accumulated Deficit)		$ 1.2

Net revenues (Details)

Net revenues (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017
Concentration Risk [Line Items]
Reserve for returns and allowances	$ 4.6	$ 4.4
Reserve for the customer incentive programs, including distributor rebates	$ 17.1	$ 10.2
Sales Revenue, Net | Hospitals And Healthcare Providers | Customer Concentration Risk
Concentration Risk [Line Items]
Percentage of total revenue	86.00%
Sales Revenue, Net | Other Medical Device Manufacturers | Customer Concentration Risk
Concentration Risk [Line Items]
Percentage of total revenue	10.00%
Sales Revenue, Net | Home Care Providers | Customer Concentration Risk
Concentration Risk [Line Items]
Percentage of total revenue	4.00%

Net revenues Other revenues (De

Net revenues Other revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Revenue, Major Customer [Line Items]
Net revenues	$ 609,672	$ 534,703	$ 1,806,768	$ 1,551,197
Vascular access
Revenue, Major Customer [Line Items]
Net revenues	142,712	133,521	427,557	396,866
Anesthesia
Revenue, Major Customer [Line Items]
Net revenues	87,973	87,964	263,202	255,107
Interventional
Revenue, Major Customer [Line Items]
Net revenues	79,404	69,186	228,262	181,577
Surgical
Revenue, Major Customer [Line Items]
Net revenues	89,910	85,210	266,049	263,254
Interventional urology
Revenue, Major Customer [Line Items]
Net revenues	48,995	0	138,969	0
OEM
Revenue, Major Customer [Line Items]
Net revenues	54,838	48,589	153,286	137,067
Other (3)
Revenue, Major Customer [Line Items]
Net revenues	$ 105,840	$ 110,233	$ 329,443	$ 317,326

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - USD ($) $ in Thousands	Jun. 21, 2018	Oct. 02, 2017	Jul. 09, 2018	Dec. 31, 2017	Sep. 30, 2018	Feb. 17, 2017
Business Acquisition [Line Items]
Payments to acquire intangible assets	$ 20,600
Consideration transferred				$ 2,000,000
Contingent consideration liabilities				$ 272,136	$ 244,574
Aggregate milestone payment, maximum					325,000
Vascular Solutions, Inc.
Business Acquisition [Line Items]
Net assets acquired						$ 975,500
NeoTract
Business Acquisition [Line Items]
Cash payment to acquire business		$ 725,600
Business acquisition working capital adjustment		1,400
Contingent consideration liabilities					229,400
Aggregate milestone payment, maximum		$ 300,000			$ 300,000
Milestone payment			$ 75,000

Acquisitions - Pro Forma (Detai

Acquisitions - Pro Forma (Details) - Vascular Solutions, Inc. - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	9 Months Ended
	Oct. 01, 2017	Oct. 01, 2017
Business Acquisition [Line Items]
Net revenue	$ 568,437	$ 1,660,591
Net income	$ 52,909	$ 157,249
Net Income, Basic earnings per common share (in USD per share)	$ 1.17	$ 3.50
Net Income, Diluted earnings per common share (in USD per share)	$ 1.14	$ 3.37
Basic, weighted average common shares outstanding (in shares)	45,035	44,975
Diluted, weighted average common shares outstanding (in shares)	46,587	46,673

Restructuring charges and imp_3

Restructuring charges and impairment charges - Charges Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1,964	$ (92)	$ 58,515	$ 13,723
Asset impairment charges	17,245		19,110
Restructuring and impairment charges	19,209	(92)	77,625	13,723
Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,587	(554)	57,160	12,807
Asset impairment charges	0		0
Restructuring and impairment charges	1,587		57,160
Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	377	$ 462	1,355	916
Asset impairment charges	17,245		19,110
Restructuring and impairment charges	17,622		20,465
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,264		53,738
2018 Footprint realignment plan | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,119		53,463
2018 Footprint realignment plan | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	145		275
Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	700		1,981	1,859
Other restructuring programs | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	468		1,318	1,352
Other restructuring programs | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 232		663	507
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges			2,796	1,332
2016 Footprint realignment plan | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges			2,379	1,099
2016 Footprint realignment plan | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 417	233
Vascular Solutions integration program
Restructuring Cost and Reserve [Line Items]
Restructuring charges				4,626
Vascular Solutions integration program | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges				4,534
Vascular Solutions integration program | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges				92
2017 EMEA restructuring program
Restructuring Cost and Reserve [Line Items]
Restructuring charges				5,906
2017 EMEA restructuring program | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges				5,822
2017 EMEA restructuring program | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges				$ 84

Restructuring charges and imp_4

Restructuring charges and impairment charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017	May 01, 2018
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	$ 17,245		$ 19,110
Employee termination benefits
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	0		0
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring costs expected cash payment	1,800		2,800
Restructuring reserve	51,600		51,600
2018 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					$ 102,000
2018 Footprint realignment plan | Minimum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					40,000
2018 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					133,000
2018 Footprint realignment plan | Maximum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					$ 59,000
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	43,000		43,000
Aggregate restructuring charges incurred	17,400		17,400
Restructuring reserve	5,900		5,900
2016 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1,700	$ 1,400	5,100	$ 5,500
Aggregate restructuring charges incurred	19,800		19,800
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			28,700
Aggregate restructuring charges incurred	12,400		12,400
Restructuring reserve	3,800		3,800
2014 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	800	$ 1,000	1,800	$ 3,100
2014 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	46,000		46,000
2014 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	51,000		$ 51,000
Intellectual property
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	17,200
Asset impairment charges, net of tax	$ 9,200

Restructuring charges and imp_5

Restructuring charges and impairment charges - Charges By Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1,964	$ (92)	$ 58,515	$ 13,723
Vascular North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	203	582	725	1,663
Interventional North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	(26)	(228)	881	4,178
Anesthesia North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	38	220	164	1,031
EMEA
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,520	(632)	54,310	6,483
All Other
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 229	$ (34)	$ 2,435	$ 368

Restructuring charges and imp_6

Restructuring charges and impairment charges - Cost Estimates By Major Type of Expense (Details) - 2018 Footprint realignment plan $ in Millions	May 01, 2018USD ($)
Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 102
Minimum | Termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	60
Minimum | Other exit costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2
Minimum | Special Termination Benefit And Other Restructuring
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	62
Minimum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	40
Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	133
Maximum | Termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	70
Maximum | Other exit costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4
Maximum | Special Termination Benefit And Other Restructuring
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	74
Maximum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 59

Inventories, net (Detail)

Inventories, net (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 105,600	$ 98,451
Work-in-process	65,291	62,381
Finished goods	240,175	234,912
Inventories, net	$ 411,066	$ 395,744

Goodwill and other intangible_3

Goodwill and other intangible assets, net - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Oct. 01, 2017
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets		$ 19,110	$ 0
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets	$ 16,900
Impairment of long-lived assets, net of tax	$ 8,900

Goodwill and other intangible_4

Goodwill and other intangible assets, net - Changes in carrying amount of goodwill, by reporting segment (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 2,235,592
Goodwill related to acquisitions	578
Currency translation adjustment	(12,741)
Goodwill, ending balance	2,223,429
Vascular North America
Goodwill [Roll Forward]
Goodwill, beginning balance	264,869
Goodwill related to acquisitions	0
Currency translation adjustment	0
Goodwill, ending balance	264,869
Interventional North America
Goodwill [Roll Forward]
Goodwill, beginning balance	433,049
Goodwill related to acquisitions	1,027
Currency translation adjustment	(1,934)
Goodwill, ending balance	432,142
Anesthesia North America
Goodwill [Roll Forward]
Goodwill, beginning balance	157,289
Goodwill related to acquisitions	0
Currency translation adjustment	(634)
Goodwill, ending balance	156,655
Surgical North America
Goodwill [Roll Forward]
Goodwill, beginning balance	250,912
Goodwill related to acquisitions	0
Currency translation adjustment	0
Goodwill, ending balance	250,912
EMEA
Goodwill [Roll Forward]
Goodwill, beginning balance	494,548
Goodwill related to acquisitions	(27)
Currency translation adjustment	(7,778)
Goodwill, ending balance	486,743
Asia
Goodwill [Roll Forward]
Goodwill, beginning balance	209,200
Goodwill related to acquisitions	(9)
Currency translation adjustment	(3,079)
Goodwill, ending balance	206,112
OEM
Goodwill [Roll Forward]
Goodwill, beginning balance	4,883
Goodwill related to acquisitions	0
Currency translation adjustment	0
Goodwill, ending balance	4,883
All Other
Goodwill [Roll Forward]
Goodwill, beginning balance	420,842
Goodwill related to acquisitions	(413)
Currency translation adjustment	684
Goodwill, ending balance	$ 421,113

Goodwill and other intangible_5

Goodwill and other intangible assets, net - Components of intangible assets (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,940,362	$ 2,964,632
Accumulated Amortization	(677,544)	(580,884)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
In-process research and development	29,377	34,672
Accumulated Amortization	0	0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	1,020,603	1,023,837
Accumulated Amortization	(314,051)	(281,263)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	1,273,503	1,287,487
Accumulated Amortization	(305,350)	(258,580)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	23,637	23,697
Accumulated Amortization	(17,756)	(16,996)
Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	569,570	571,510
Accumulated Amortization	(33,001)	(22,069)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	23,672	23,429
Accumulated Amortization	$ (7,386)	$ (1,976)

Financial instruments - Additio

Financial instruments - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017	Dec. 31, 2017
Derivatives Fair Value [Line Items]
Net revenues	$ 609,672,000	$ 534,703,000	$ 1,806,768,000	$ 1,551,197,000
Spain, Italy, Portugal, and Greece
Derivatives Fair Value [Line Items]
Net revenues			107,700,000	96,000,000
Cash flow hedging
Derivatives Fair Value [Line Items]
Ineffectiveness related to derivatives	0	0	0	0
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	127,500,000		127,500,000		$ 88,500,000
Foreign exchange contract | Not Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Loss related to currency forward contracts	1,000,000	$ 600,000	300,000	$ 3,700,000
Total notional amount for all open foreign currency forward contracts	$ 124,600,000		$ 124,600,000		$ 110,600,000

Financial instruments - Fair va

Financial instruments - Fair values of derivative instruments designated as hedging instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 2,333	$ 1,221
Total liability derivatives	1,636	1,426
Foreign exchange contract | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	2,333	1,221
Foreign exchange contract | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	1,636	1,426
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	2,158	914
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	572	1,373
Foreign exchange contract | Not Designated as Hedging Instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	175	307
Foreign exchange contract | Not Designated as Hedging Instrument | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 1,064	$ 53

Financial instruments - Aggrega

Financial instruments - Aggregate accounts receivable, net of allowance for doubtful accounts (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts receivable	$ 9,657	$ 10,255
Allowance for doubtful accounts receivable, current	3,900	3,500
Spain, Italy, Portugal, and Greece
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal	$ 51,468	$ 49,054
Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal	14.10%	14.60%
Long-term portion of accounts receivable, net	$ 4,200	$ 3,300

Fair value measurement - Financ

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 9,849	$ 9,045
Derivative assets	2,333	1,221
Derivative liabilities	1,636	1,426
Contingent consideration liabilities	244,574	272,136
Quoted prices in active markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	9,849	9,045
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	0	0
Significant other observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	2,333	1,221
Derivative liabilities	1,636	1,426
Contingent consideration liabilities	0	0
Significant unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	$ 244,574	$ 272,136

Fair value measurement - Narrat

Fair value measurement - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Jul. 09, 2018	Sep. 30, 2018	Oct. 02, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate milestone payment, maximum		$ 325
NeoTract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate milestone payment, maximum		$ 300	$ 300
Milestone payment	$ 75

Fair value measurement - Valuat

Fair value measurement - Valuation technique and inputs used in determining the fair value of contingent consideration (Details)	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Contingent consideration, revenue volatility, percentage	24.10%

Fair value measurement - Reconc

Fair value measurement - Reconciliation of changes in financial liabilities measured on recurring basis (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 272,136
Additions	396
Payments (2)	(75,252)
Revaluations	47,344
Translation adjustment	(50)
Ending balance	$ 244,574

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Equity Option
Shareholders Equity [Line Items]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	0.7	0.6	0.7	0.6
Convertible Debt
Shareholders Equity [Line Items]
Debt instrument, face amount	$ 400		$ 400

Shareholders' equity - Reconcil

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Equity [Abstract]
Basic (in shares)	45,851	45,035	45,587	44,975
Dilutive effect of share-based awards (in shares)	919	934	1,007	873
Dilutive effect of convertible notes and warrants (in shares)	45	618	191	825
Diluted (in shares)	46,815	46,587	46,785	46,673

Shareholders' equity - Change i

Shareholders' equity - Change in accumulated other comprehensive income, net of tax (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			$ 2,430,531
Other comprehensive income (loss) before reclassifications			(27,187)	$ 158,345
Amounts reclassified from accumulated other comprehensive income	$ 1,214	$ 182	3,111	4,922
Net current-period other comprehensive income (loss)			(24,076)	163,267
Ending Balance	2,507,065		2,507,065
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			340	(2,424)
Other comprehensive income (loss) before reclassifications			2,816	3,383
Amounts reclassified from accumulated other comprehensive income			(873)	1,535
Net current-period other comprehensive income (loss)			1,943	4,918
Ending Balance	2,283	2,494	2,283	2,494
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(138,808)	(136,596)
Other comprehensive income (loss) before reclassifications			127	(1,050)
Amounts reclassified from accumulated other comprehensive income	1,276	1,124	3,984	3,387
Net current-period other comprehensive income (loss)			4,111	2,337
Ending Balance	(134,697)	(134,259)	(134,697)	(134,259)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(126,623)	(299,697)
Other comprehensive income (loss) before reclassifications			(30,130)	156,012
Amounts reclassified from accumulated other comprehensive income			0	0
Net current-period other comprehensive income (loss)			(30,130)	156,012
Ending Balance	(156,753)	(143,685)	(156,753)	(143,685)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(265,091)	(438,717)
Ending Balance	$ (289,167)	$ (275,450)	$ (289,167)	$ (275,450)

Shareholders' equity - Accumula

Shareholders' equity - Accumulated other comprehensive income into income expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ 267,099	$ 239,476	$ 788,147	$ 710,126
Total before tax	(55,254)	(89,376)	(123,451)	(217,514)
(Benefit) taxes on income from continuing operations	(1,286)	9,978	14,532	19,404
Net of tax	(56,540)	(79,398)	(108,919)	(198,110)
Total reclassifications, net of tax	1,214	182	3,111	4,922
Actuarial losses
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,640	1,723	5,120	5,176
Prior-service costs
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	24	20	71	79
Pension and Other Postretirement Benefits Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,664	1,743	5,191	5,255
Tax benefit	(388)	(619)	(1,207)	(1,868)
Total reclassifications, net of tax	1,276	1,124	3,984	3,387
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign exchange contract | Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	(87)	(1,179)	(1,038)	1,769
Total before tax	(87)	(1,179)	(1,038)	1,769
(Benefit) taxes on income from continuing operations	25	237	165	(234)
Net of tax	$ (62)	$ (942)	$ (873)	$ 1,535

Taxes on income from continui_3

Taxes on income from continuing operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Income Tax Disclosure [Abstract]
Tax cuts and jobs act of 2017, tax benefit to adjust its initial provisional estimates	$ 2.1
Effective income tax rate	(2.30%)	11.20%	11.80%	8.90%

Pension and other postretirem_3

Pension and other postretirement benefits (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 380	$ 725	$ 1,135	$ 2,162
Interest cost	3,681	3,773	11,119	11,347
Expected return on plan assets	(7,423)	(6,607)	(22,260)	(20,100)
Net amortization and deferral	1,687	1,668	5,090	5,049
Net benefits expense (income)	(1,675)	(441)	(4,916)	(1,542)
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	(66)	61	38	210
Interest cost	285	426	1,042	1,183
Expected return on plan assets	0	0	0	0
Net amortization and deferral	(23)	75	101	206
Net benefits expense (income)	$ 196	$ 562	$ 1,181	$ 1,599

Commitments and contingent li_2

Commitments and contingent liabilities (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2018USD ($)
Loss Contingencies [Line Items]
Estimated litigation liability	$ 1.8
Minimum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out	15 years
Maximum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out	20 years
Accrued Liabilities
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies	$ 1
Other Liability
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies	$ 5.5

Segment information (Details)

Segment information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 609,672	$ 534,703	$ 1,806,768	$ 1,551,197
Operating profit	82,105	110,354	202,438	281,375
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	126,358	123,161	347,550	340,261
Unallocated expenses
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	(44,253)	(12,807)	(145,112)	(58,886)
Vascular North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	80,719	75,065	243,829	232,872
Vascular North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	24,287	17,803	73,585	54,565
Interventional North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	66,726	60,719	191,878	159,002
Interventional North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	17,142	12,485	47,772	13,265
Anesthesia North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	53,160	50,819	154,215	148,107
Anesthesia North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	16,811	15,084	48,860	48,444
Surgical North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	42,545	40,804	123,930	131,464
Surgical North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	15,906	13,618	47,709	47,285
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	139,541	137,034	452,826	409,077
EMEA | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	21,916	24,198	80,221	69,102
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	76,544	74,202	207,201	190,368
Asia | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	20,834	20,427	54,948	50,252
OEM
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	54,838	48,589	153,286	137,067
OEM | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	15,049	12,256	37,617	31,714
All other
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	95,599	47,471	279,603	143,240
All other | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	$ (5,587)	$ 7,290	$ (43,162)	$ 25,634

Segment information Total net r

Segment information Total net revenues by geographic region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Segment Reporting Information [Line Items]
Net revenues	$ 609,672	$ 534,703	$ 1,806,768	$ 1,551,197
United States
Segment Reporting Information [Line Items]
Net revenues	365,271	306,763	1,066,095	903,201
Europe
Segment Reporting Information [Line Items]
Net revenues	160,498	148,808	500,697	434,223
Asia
Segment Reporting Information [Line Items]
Net revenues	60,414	59,169	170,458	156,074
All Other
Segment Reporting Information [Line Items]
Net revenues	$ 23,489	$ 19,963	$ 69,518	$ 57,699

Condensed consolidating guara_3

Condensed consolidating guarantor financial information - Additional Information (Detail) - Senior Notes	Sep. 30, 2018USD ($)
Condensed Financial Statements Captions [Line Items]
Ownership percentage	100.00%
5.25% Senior Notes due 2024
Condensed Financial Statements Captions [Line Items]
Debt instrument, face amount	$ 250,000,000
Debt instrument, stated interest rate	5.25%
4.875% Senior Notes Due 2026
Condensed Financial Statements Captions [Line Items]
Debt instrument, face amount	$ 400,000,000
Debt instrument, stated interest rate	4.875%
4.625% Senior Notes due 2027
Condensed Financial Statements Captions [Line Items]
Debt instrument, face amount	$ 500,000,000
Debt instrument, stated interest rate	4.625%

Condensed consolidating guara_4

Condensed consolidating guarantor financial information - Income and Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017	Sep. 30, 2018	Oct. 01, 2017
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 609,672	$ 534,703	$ 1,806,768	$ 1,551,197
Cost of goods sold	267,099	239,476	788,147	710,126
Gross profit	342,573	295,227	1,018,621	841,071
Selling, general and administrative expenses	214,894	163,771	660,148	486,674
Research and development expenses	26,365	21,194	78,410	59,299
Restructuring and impairment charges (credits)	19,209	(92)	77,625	13,723
Income from continuing operations before interest, loss on extinguishment of debt and taxes	82,105	110,354	202,438	281,375
Interest, net	26,851	20,978	78,987	58,268
Loss on extinguishment of debt	0	0	0	5,593
Income from continuing operations before taxes	55,254	89,376	123,451	217,514
(Benefit) taxes on (loss) income from continuing operations	(1,286)	9,978	14,532	19,404
Equity in net income of consolidated subsidiaries	0	0	0	0
Income from continuing operations	56,540	79,398	108,919	198,110
Operating loss from discontinued operations	(83)	(3,749)	1,246	(4,597)
Benefit on loss from discontinued operations	(67)	(1,366)	(47)	(1,675)
Income (loss) from discontinued operations	(16)	(2,383)	1,293	(2,922)
Net income	56,524	77,015	110,212	195,188
Other comprehensive income	17,253	43,845	(24,076)	163,267
Comprehensive income	73,777	120,860	86,136	358,455
Eliminations
Condensed Income Statements, Captions [Line Items]
Net revenues	(111,299)	(104,024)	(331,214)	(315,085)
Cost of goods sold	(111,411)	(104,088)	(324,994)	(311,977)
Gross profit	112	64	(6,220)	(3,108)
Selling, general and administrative expenses	(22)	(126)	(352)	398
Research and development expenses	0	0	0	0
Restructuring and impairment charges (credits)	0	0	0	0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	134	190	(5,868)	(3,506)
Interest, net	0	0	0	0
Loss on extinguishment of debt				0
Income from continuing operations before taxes	134	190	(5,868)	(3,506)
(Benefit) taxes on (loss) income from continuing operations	13	6	(1,090)	(593)
Equity in net income of consolidated subsidiaries	(149,322)	(158,701)	(347,794)	(442,406)
Income from continuing operations	(149,201)	(158,517)	(352,572)	(445,319)
Operating loss from discontinued operations	0	0	0	0
Benefit on loss from discontinued operations	0	0	0	0
Income (loss) from discontinued operations	0	0	0	0
Net income	(149,201)	(158,517)	(352,572)	(445,319)
Other comprehensive income	(31,054)	(86,482)	57,242	(327,288)
Comprehensive income	(180,255)	(244,999)	(295,330)	(772,607)
Parent Company
Condensed Income Statements, Captions [Line Items]
Net revenues	0	0	0	0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	11,347	10,536	32,958	38,523
Research and development expenses	378	220	1,094	719
Restructuring and impairment charges (credits)	0	0	0	0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	(11,725)	(10,756)	(34,052)	(39,242)
Interest, net	25,191	29,231	72,120	80,737
Loss on extinguishment of debt				5,593
Income from continuing operations before taxes	(36,916)	(39,987)	(106,172)	(125,572)
(Benefit) taxes on (loss) income from continuing operations	(13,449)	(21,968)	(39,859)	(57,679)
Equity in net income of consolidated subsidiaries	80,007	97,417	176,511	266,003
Income from continuing operations	56,540	79,398	110,198	198,110
Operating loss from discontinued operations	(83)	(3,749)	(33)	(4,597)
Benefit on loss from discontinued operations	(67)	(1,366)	(47)	(1,675)
Income (loss) from discontinued operations	(16)	(2,383)	14	(2,922)
Net income	56,524	77,015	110,212	195,188
Other comprehensive income	17,253	43,845	(24,076)	163,267
Comprehensive income	73,777	120,860	86,136	358,455
Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	398,961	335,051	1,169,684	989,314
Cost of goods sold	232,209	194,262	681,300	576,465
Gross profit	166,752	140,789	488,384	412,849
Selling, general and administrative expenses	130,773	89,315	401,252	278,529
Research and development expenses	19,482	14,788	57,668	39,568
Restructuring and impairment charges (credits)	17,128	552	20,581	7,261
Income from continuing operations before interest, loss on extinguishment of debt and taxes	(631)	36,134	8,883	87,491
Interest, net	1,057	(9,102)	5,066	(25,245)
Loss on extinguishment of debt				0
Income from continuing operations before taxes	(1,688)	45,236	3,817	112,736
(Benefit) taxes on (loss) income from continuing operations	(2,562)	14,576	11,347	33,873
Equity in net income of consolidated subsidiaries	68,943	61,027	170,276	175,690
Income from continuing operations	69,817	91,687	162,746	254,553
Operating loss from discontinued operations	0	0	0	0
Benefit on loss from discontinued operations	0	0	0	0
Income (loss) from discontinued operations	0	0	0	0
Net income	69,817	91,687	162,746	254,553
Other comprehensive income	14,107	30,196	(30,691)	147,727
Comprehensive income	83,924	121,883	132,055	402,280
Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	322,010	303,676	968,298	876,968
Cost of goods sold	146,301	149,302	431,841	445,638
Gross profit	175,709	154,374	536,457	431,330
Selling, general and administrative expenses	72,796	64,046	226,290	169,224
Research and development expenses	6,505	6,186	19,648	19,012
Restructuring and impairment charges (credits)	2,081	(644)	57,044	6,462
Income from continuing operations before interest, loss on extinguishment of debt and taxes	94,327	84,786	233,475	236,632
Interest, net	603	849	1,801	2,776
Loss on extinguishment of debt				0
Income from continuing operations before taxes	93,724	83,937	231,674	233,856
(Benefit) taxes on (loss) income from continuing operations	14,712	17,364	44,134	43,803
Equity in net income of consolidated subsidiaries	372	257	1,007	713
Income from continuing operations	79,384	66,830	188,547	190,766
Operating loss from discontinued operations	0	0	1,279	0
Benefit on loss from discontinued operations	0	0	0	0
Income (loss) from discontinued operations	0	0	1,279	0
Net income	79,384	66,830	189,826	190,766
Other comprehensive income	16,947	56,286	(26,551)	179,561
Comprehensive income	$ 96,331	$ 123,116	$ 163,275	$ 370,327

Condensed consolidating guara_5

Condensed consolidating guarantor financial information - Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Oct. 01, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 356,276	$ 333,558	$ 1,017,573	$ 543,789
Accounts receivable, net	374,341	345,875
Accounts receivable from consolidated subsidiaries	0	0
Inventories, net	411,066	395,744
Prepaid expenses and other current assets	55,173	47,882
Prepaid taxes	40,715	5,748
Assets held for sale	3,239	0
Total current assets	1,240,810	1,128,807
Property, plant and equipment, net	421,265	382,999
Goodwill	2,223,429	2,235,592
Intangible assets, net	2,262,818	2,383,748
Investments in consolidated subsidiaries	0	0
Deferred tax assets	2,305	3,810
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	50,093	46,536
Total assets	6,200,720	6,181,492
Current liabilities
Current borrowings	77,250	86,625
Accounts payable	97,628	92,027
Accounts payable to consolidated subsidiaries	0	0
Accrued expenses	105,584	96,853
Current portion of contingent consideration	102,664	74,224
Payroll and benefit-related liabilities	94,132	107,415
Accrued interest	20,623	6,165
Income taxes payable	13,347	11,514
Other current liabilities	38,065	9,053
Total current liabilities	549,293	483,876
Long-term borrowings	2,075,834	2,162,927
Deferred tax liabilities	606,082	603,676
Pension and postretirement benefit liabilities	99,350	121,410
Noncurrent liability for uncertain tax positions	13,170	12,296
Notes payable and other amounts due to consolidated subsidiaries	0	0
Noncurrent contingent consideration	141,910	197,912
Other liabilities	208,016	168,864
Total liabilities	3,693,655	3,750,961
Total shareholders' equity	2,507,065	2,430,531
Total liabilities and shareholders' equity	6,200,720	6,181,492
Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	5,015	4,663
Accounts receivable from consolidated subsidiaries	(1,370,582)	(1,534,839)
Inventories, net	(32,318)	(26,279)
Prepaid expenses and other current assets	3,982	3,982
Prepaid taxes	0	0
Assets held for sale	0
Total current assets	(1,393,903)	(1,552,473)
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Investments in consolidated subsidiaries	(7,623,587)	(7,499,941)
Deferred tax assets	(2,284)	(2,261)
Notes receivable and other amounts due from consolidated subsidiaries	(4,710,847)	(4,683,933)
Other assets	0	0
Total assets	(13,730,621)	(13,738,608)
Current liabilities
Current borrowings	0	0
Accounts payable	0	0
Accounts payable to consolidated subsidiaries	(1,370,582)	(1,534,839)
Accrued expenses	0	0
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	0	0
Accrued interest	0	0
Income taxes payable	(1,090)	0
Other current liabilities	0	0
Total current liabilities	(1,371,672)	(1,534,839)
Long-term borrowings	0	0
Deferred tax liabilities	(2,284)	(2,261)
Pension and postretirement benefit liabilities	0	0
Noncurrent liability for uncertain tax positions	0	0
Notes payable and other amounts due to consolidated subsidiaries	(4,710,847)	(4,683,933)
Noncurrent contingent consideration	0	0
Other liabilities	0	0
Total liabilities	(6,084,803)	(6,221,033)
Total shareholders' equity	(7,645,818)	(7,517,575)
Total liabilities and shareholders' equity	(13,730,621)	(13,738,608)
Parent Company
Current assets
Cash and cash equivalents	47,766	37,803	45,189	14,571
Accounts receivable, net	2,932	2,414
Accounts receivable from consolidated subsidiaries	24,606	14,478
Inventories, net	0	0
Prepaid expenses and other current assets	14,379	14,874
Prepaid taxes	33,766	0
Assets held for sale	0
Total current assets	123,449	69,569
Property, plant and equipment, net	3,177	2,088
Goodwill	0	0
Intangible assets, net	95	0
Investments in consolidated subsidiaries	5,929,366	5,806,244
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	2,265,457	2,452,101
Other assets	30,226	31,173
Total assets	8,351,770	8,361,175
Current liabilities
Current borrowings	27,250	36,625
Accounts payable	4,254	4,269
Accounts payable to consolidated subsidiaries	1,024,109	1,211,568
Accrued expenses	17,966	17,957
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	18,184	21,145
Accrued interest	20,595	6,133
Income taxes payable	0	4,352
Other current liabilities	1,637	1,461
Total current liabilities	1,113,995	1,303,510
Long-term borrowings	2,075,834	2,162,927
Deferred tax liabilities	92,270	88,512
Pension and postretirement benefit liabilities	49,853	70,860
Noncurrent liability for uncertain tax positions	1,986	1,117
Notes payable and other amounts due to consolidated subsidiaries	2,370,469	2,155,146
Noncurrent contingent consideration	0	0
Other liabilities	140,298	148,572
Total liabilities	5,844,705	5,930,644
Total shareholders' equity	2,507,065	2,430,531
Total liabilities and shareholders' equity	8,351,770	8,361,175
Guarantor Subsidiaries
Current assets
Cash and cash equivalents	1,288	8,933	748,412	1,031
Accounts receivable, net	55,452	57,818
Accounts receivable from consolidated subsidiaries	994,236	1,177,246
Inventories, net	245,600	245,533
Prepaid expenses and other current assets	12,409	9,236
Prepaid taxes	0	0
Assets held for sale	3,239
Total current assets	1,312,224	1,498,766
Property, plant and equipment, net	238,079	213,663
Goodwill	1,245,455	1,246,144
Intangible assets, net	1,274,994	1,355,275
Investments in consolidated subsidiaries	1,673,596	1,674,077
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	2,445,390	2,231,832
Other assets	6,057	6,397
Total assets	8,195,795	8,226,154
Current liabilities
Current borrowings	0	0
Accounts payable	54,791	46,992
Accounts payable to consolidated subsidiaries	280,381	261,121
Accrued expenses	36,206	31,827
Current portion of contingent consideration	101,573	74,224
Payroll and benefit-related liabilities	31,405	44,009
Accrued interest	0	0
Income taxes payable	0	0
Other current liabilities	33,589	3,775
Total current liabilities	537,945	461,948
Long-term borrowings	0	0
Deferred tax liabilities	264,288	265,426
Pension and postretirement benefit liabilities	32,019	32,750
Noncurrent liability for uncertain tax positions	8,352	8,196
Notes payable and other amounts due to consolidated subsidiaries	2,135,450	2,320,611
Noncurrent contingent consideration	131,578	186,923
Other liabilities	9,026	7,850
Total liabilities	3,118,658	3,283,704
Total shareholders' equity	5,077,137	4,942,450
Total liabilities and shareholders' equity	8,195,795	8,226,154
Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	307,222	286,822	$ 223,972	$ 528,187
Accounts receivable, net	310,942	280,980
Accounts receivable from consolidated subsidiaries	351,740	343,115
Inventories, net	197,784	176,490
Prepaid expenses and other current assets	24,403	19,790
Prepaid taxes	6,949	5,748
Assets held for sale	0
Total current assets	1,199,040	1,112,945
Property, plant and equipment, net	180,009	167,248
Goodwill	977,974	989,448
Intangible assets, net	987,729	1,028,473
Investments in consolidated subsidiaries	20,625	19,620
Deferred tax assets	4,589	6,071
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	13,810	8,966
Total assets	3,383,776	3,332,771
Current liabilities
Current borrowings	50,000	50,000
Accounts payable	38,583	40,766
Accounts payable to consolidated subsidiaries	66,092	62,150
Accrued expenses	51,412	47,069
Current portion of contingent consideration	1,091	0
Payroll and benefit-related liabilities	44,543	42,261
Accrued interest	28	32
Income taxes payable	14,437	7,162
Other current liabilities	2,839	3,817
Total current liabilities	269,025	253,257
Long-term borrowings	0	0
Deferred tax liabilities	251,808	251,999
Pension and postretirement benefit liabilities	17,478	17,800
Noncurrent liability for uncertain tax positions	2,832	2,983
Notes payable and other amounts due to consolidated subsidiaries	204,928	208,176
Noncurrent contingent consideration	10,332	10,989
Other liabilities	58,692	12,442
Total liabilities	815,095	757,646
Total shareholders' equity	2,568,681	2,575,125
Total liabilities and shareholders' equity	$ 3,383,776	$ 3,332,771

Condensed consolidating guara_6

Condensed consolidating guarantor financial information - Cash Flows (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Oct. 01, 2017
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	$ 302,944	$ 319,708
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(55,751)	(53,977)
Proceeds from sale of investments	0	6,332
Payments for businesses and intangibles acquired, net of cash acquired	(22,550)	(1,010,711)
Net cash used in investing activities from continuing operations	(78,301)	(1,058,356)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	1,963,500
Reduction in borrowings	(98,500)	(747,576)
Debt extinguishment, issuance and amendment fees	(188)	(19,114)
Net proceeds from share based compensation plans and the related tax impacts	18,666	4,739
Payments for contingent consideration	(73,152)	(245)
Dividends paid	(46,526)	(45,905)
Intercompany transactions	0	0
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	(199,700)	1,155,399
Cash flows from discontinued operations:
Net cash used in operating activities	(701)	(1,140)
Net cash used in discontinued operations	(701)	(1,140)
Effect of exchange rate changes on cash and cash equivalents	(1,524)	58,173
Net increase in cash and cash equivalents	22,718	473,784
Cash and cash equivalents at the beginning of the period	333,558	543,789
Cash and cash equivalents at the end of the period	356,276	1,017,573
Eliminations
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(145,626)	(61,918)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	0	0
Proceeds from sale of investments	(28,239)	(464,982)
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Net cash used in investing activities from continuing operations	(28,239)	(464,982)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0	0
Dividends paid	0	0
Intercompany transactions	28,239	464,982
Intercompany dividends paid	145,626	61,918
Net cash provided by (used in) financing activities from continuing operations	173,865	526,900
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	0	0
Cash and cash equivalents at the beginning of the period	0	0
Cash and cash equivalents at the end of the period	0	0
Parent Company
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(202,209)	(156,643)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(1,524)	(233)
Proceeds from sale of investments	28,239	464,982
Payments for businesses and intangibles acquired, net of cash acquired	(100)	(975,524)
Net cash used in investing activities from continuing operations	26,615	(510,775)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		1,963,500
Reduction in borrowings	(98,500)	(747,576)
Debt extinguishment, issuance and amendment fees	(188)	(19,114)
Net proceeds from share based compensation plans and the related tax impacts	18,666	4,739
Payments for contingent consideration	0	0
Dividends paid	(46,526)	(45,905)
Intercompany transactions	312,806	(456,468)
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	186,258	699,176
Cash flows from discontinued operations:
Net cash used in operating activities	(701)	(1,140)
Net cash used in discontinued operations	(701)	(1,140)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	9,963	30,618
Cash and cash equivalents at the beginning of the period	37,803	14,571
Cash and cash equivalents at the end of the period	47,766	45,189
Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	382,389	300,961
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(23,686)	(27,527)
Proceeds from sale of investments	0	0
Payments for businesses and intangibles acquired, net of cash acquired	1,404	0
Net cash used in investing activities from continuing operations	(22,282)	(27,527)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	(73,152)	(245)
Dividends paid	0	0
Intercompany transactions	(294,600)	474,192
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	(367,752)	473,947
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	(7,645)	747,381
Cash and cash equivalents at the beginning of the period	8,933	1,031
Cash and cash equivalents at the end of the period	1,288	748,412
Non-Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	268,390	237,308
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(30,541)	(26,217)
Proceeds from sale of investments	0	6,332
Payments for businesses and intangibles acquired, net of cash acquired	(23,854)	(35,187)
Net cash used in investing activities from continuing operations	(54,395)	(55,072)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0	0
Dividends paid	0	0
Intercompany transactions	(46,445)	(482,706)
Intercompany dividends paid	(145,626)	(61,918)
Net cash provided by (used in) financing activities from continuing operations	(192,071)	(544,624)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	(1,524)	58,173
Net increase in cash and cash equivalents	20,400	(304,215)
Cash and cash equivalents at the beginning of the period	286,822	528,187
Cash and cash equivalents at the end of the period	$ 307,222	$ 223,972

Subsequent events (Details)

Subsequent events (Details) - Subsequent Event	Oct. 04, 2018USD ($)	Oct. 04, 2018EUR (€)instrument	Oct. 03, 2018USD ($)
Essential Medical, Inc.
Subsequent Event [Line Items]
Cash payment to acquire business	$ 60,000,000
Additional payments to acquire businesses	$ 100,000,000
Cross Currency Interest Rate Contract | Designated as Hedging Instrument
Subsequent Event [Line Items]
Derivative, number of instruments held | instrument		6
Derivative, notional amount		€ 433,900,000	$ 500,000,000
Derivative, fixed interest rate		1.942%	4.625%

Uncategorized Items - tfx-20180

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 3,076,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 3,076,000